There are many complications in developing and testing new active ligands with greater specificity for pro-survival NTF receptors. Due to those difficulties, there were strategies developed to avoid receptor *per se* and activate downstream pro-survival pathways. There is still an incomplete understanding of the complexity of NT receptors signaling pathways, in particular to differentiate between target-mediated and cell body-mediated neurotrophin signaling. Zhou et al. (2005) hypothesized that stable activation of pro-survival ERK1/2 kinase, which is a downstream effector of Trk receptors, inhibits RGC death. Since MEK1 is a direct upstream activator of ERK1/2, increase in MEK1 should activate ERK1/2 expression. The authors found significant RGC protection in the AAV-MEK1 mice, with up to 60% greater survival compared to control mice after the 5th week of treatment (Zhou et al., 2005). Another study evaluated the neuroprotective effect of modification of downstream NTs effectors. A NK-4 cyanine dye produced neurotrophic effects and promoted neuriteoutgrowth and cell proliferation of PC12 cells. Action of NK-4 was dependent on activation of PI3K-AKT but occurred independently of Trk. NK-4 additionally induced phosphorylation of AKT kinase. The authors showed increased cell count indicative of enhanced survival in the treated group versus control (Ohta et al., 2011).

Another key target for neuroprotection of RGCs is Rho kinase which is a member of the serine-threonine family of protein kinases activated by the small G protein Rho. Rho kinase inhibition has been shown to be beneficial for IOP regulation in patients and also enhances RGC survival and axon regeneration (Rao and Epstein, 2007). An attempt to modify downstream signaling of NT receptors was to stably inactivate Rho GTPase, which was shown previously to be a downstream effector of p75 /LINGO-1/Nogo-R complex which formation leads to cell death (Nykjaer et al., 2005). It is also known that neurotrophin (NGF, BDNF or NT-3) binding abolished RhoA activation. Inactivation of Rho proteins mimicked

peptidomimetic TrkA agonist, along with a peptidomimetic p75 antagonist prevented RGC cells loss following optic nerve transection (Lebrun-Julien et al., 2009). p75 increased production of neurotoxic proteins TNF-α and α(2)-macroglobulin. p75 was found to be expressed by the majority of glia and Muller cells and TrkA was found mainly in RGCs (Lebrun-Julien et al., 2009). In another study, wild type NGF failed to protect RGCs in tested models of glaucoma and nerve axotomy. NGF-C, a NGF selective agonist of TrkA, which does not bind to p75, was found to increase neuronal survival by 17% two weeks following axotomy and by 13% in a ocular hypertension glaucoma model. Other approaches used an anti-NGF monoclonal antibody (mAb NGF30) blocking NGF binding to p75 without changes in NGF-TrkA interaction. This treatment caused a doubling of RGC survival postaxotomy and a 15% increase in RGC survival in an ocular hypotension model. Moreover, authors tested p75 receptor antagonists (THX-B and LM-24) in ON axotomy and ocular hypotension and found 37% and 21% RGC survival in the two experimental models. Antagonists of p75 inhibit TNF-α and α(2)-macroglobulin expression and were found to be neuroprotective in ON axotomy and ocular hypertension (Bai et al, 2010). Other approaches have employed Trk B agonists to produce neuroprotective effects. Unfortunately, many TrkB agonists were not able to fully mimic neuroprotective functions of BDNF on TrkB receptors. To discover small molecules having similar potency as BDNF, the authors developed a cell-based apoptotic assay and identified a potent TrkB agonist, deoxygedunin. Deoxygeduin was able to activate only TrkB, in a BDNF-independent manner evoking antiapoptotic cell pathways (ERK1/2 and AKT activation). When intravenously injected into mice (5mg/kg), deoxygeduin penetrated the blood brain barrier and strongly mimicked

There are many complications in developing and testing new active ligands with greater specificity for pro-survival NTF receptors. Due to those difficulties, there were strategies developed to avoid receptor *per se* and activate downstream pro-survival pathways. There is still an incomplete understanding of the complexity of NT receptors signaling pathways, in particular to differentiate between target-mediated and cell body-mediated neurotrophin signaling. Zhou et al. (2005) hypothesized that stable activation of pro-survival ERK1/2 kinase, which is a downstream effector of Trk receptors, inhibits RGC death. Since MEK1 is a direct upstream activator of ERK1/2, increase in MEK1 should activate ERK1/2 expression. The authors found significant RGC protection in the AAV-MEK1 mice, with up to 60% greater survival compared to control mice after the 5th week of treatment (Zhou et al., 2005). Another study evaluated the neuroprotective effect of modification of downstream NTs effectors. A NK-4 cyanine dye produced neurotrophic effects and promoted neuriteoutgrowth and cell proliferation of PC12 cells. Action of NK-4 was dependent on activation of PI3K-AKT but occurred independently of Trk. NK-4 additionally induced phosphorylation of AKT kinase. The authors showed increased cell count indicative of

Another key target for neuroprotection of RGCs is Rho kinase which is a member of the serine-threonine family of protein kinases activated by the small G protein Rho. Rho kinase inhibition has been shown to be beneficial for IOP regulation in patients and also enhances RGC survival and axon regeneration (Rao and Epstein, 2007). An attempt to modify downstream signaling of NT receptors was to stably inactivate Rho GTPase, which was shown previously to be a downstream effector of p75 /LINGO-1/Nogo-R complex which formation leads to cell death (Nykjaer et al., 2005). It is also known that neurotrophin (NGF, BDNF or NT-3) binding abolished RhoA activation. Inactivation of Rho proteins mimicked

BDNF, in terms of its neuroprotective ability (Jang et al., 2010).

enhanced survival in the treated group versus control (Ohta et al., 2011).

the effect of neurotrophins by increasing the rate of neurite elongation. (Yamashita et al., 2005). Bertrand et al. (2007) used multiple intraocular injections of membrane permeable C3 like Rho antagonists and found that sustained Rho inactivation acts as a pro-survival mechanism following optic nerve injury showing a 1.5 fold increase in RGCs survival. Coreceptor of p75 - NogoR can activate Rho kinase in a p75 dependent manner. In neurons, Rho has been shown to play a role in the regulation of apoptosis. The Rho antagonist C3–05 (to suppress Rho activation) was tested in the rodent model of acute nerve injury. In mice and rats treated with Rho-C3–05 the extent of cell death was significantly reduced by ~50% post- injury. The correlation between Rho kinase and p75 receptor was based on colocalization of active Rho with p75 after injury. Rho inactivation after injury inhibited apoptosis by preventing the synthesis of pro-apoptotic p75 receptor (Wang et al., 2002). The Rho antagonist C3-07 was successfully used in another study resulting in survival of RGCs by 1.5 fold after optic nerve lesion (Bertrand et al., 2007).

#### **<IP_ADDRESS> Other neuroprotective approaches**

Shi et al. (2008) studied α-2-macroglobulin (α2-M) inhibitors for their neuroprotective abilities. It was found that α-2M act as a sink for NTs and therefore inhibits their bioavailability during glaucoma. The authors elevated IOP in rats by cauterization and by the Morrison's model to test their hypothesis that neutrophic deficit is due to neutralization of neutrophins by α-2M. They proved that blocking α-2M, using specific inhibiting antibodies against α-2M was protective for RGCs even without lowering IOP (29% protection). Together with normalization of IOP the neutralization effect were even more pronounced (35% protection) (Shi et al., 2008).

Erythropoietin (Epo) is a glycoprotein hormone, synthesized in the kidney secreted by interstitial cells of the adrenal cortex in response to tissue hypoxia. Epo is a neurotrophic factor that could be developed as a new drug for neurological disorders. Epo posses a specific Epo/Epo-receptor system in the CNS and cerebrospinal fluid (Buemi et al., 2002). Zhong et al. (2007) studied the neuroprotective effects of intraperitoneal administration of erythropoietin(Epo) in the DBA/2J mouse model of glaucoma. Treatment with Epo at doses of 3000, 6000, and 12,000 U/kg body weight per week promoted RGC survival in DBA/2J glaucomatous mice without affecting IOP. These results suggested that Epo may be used as a potential therapeutic neuroprotectant in glaucoma. Since Epo does not cross the bloodbrain barrier (BBB) there is a tendency to recombine its structure that way that it will became permeable to BBB. Boado et al. (2010) developed new drug (HIRMAb(IgG)-EPO fusion protein) enabling Epo to cross the BBB.

#### **2.4.5 Potential methods for NTs delivery**

Topical eye drops, intraocular injections and systemically-administered compounds have been the conventional systems for delivering drugs to glaucomatous eye. However, these methods have many limitations and disadvantages. First, there is a factor of patient compliance, efficacy, side effects and absorption of the chemical. Several methods were discovered recently to improve long-term delivery of the drug, control dosage and reduce side effects. The goal might be achieved by different strategies such a slow-release biodegradable microspheres devices commonly made of poly-DL-lactic-co-glycolic acid (PLGA). PLGA spheres can be filled with chosen NT or receptor agonist which when intraocularly injected will result in slow, sustained drug release (Ward et al., 2007). Devices can be filled with not only NTs or receptor agonist/antagonist. It could be also fortified with

Neuroprotection in Glaucoma 153

Glutamate is the main excitatory neurotransmitter that is released from photoreceptor cells and biopolar cells. Typically horizontal cells and amacrine cells modulate the electrical signal at the outer and inner plexiform layers respectively. Figure 7 shows various layers of

> NFL GCL IPL

Superior

Inferior

Temporal

INL OPL ONL Nasal

OS

Fig. 7. A. Organization of the retinal layers. Confocal microscopic image of a rat retina section. The different layers of the retina are indicated in the picture: Nerve fiber layer (NFL), Ganglion cell layer (GCL), Inner plexiform layer (IPL), Inner nuclear layer (INL), Outer plexiform layer (OPL), Outer nuclear layer (ONL) and Outer Segment (OS). B. Representative flat mount showing different areas of the retina including superior, inferior,

Once glutamate is released from the axonal terminals of bipolar cells, it will migrate through the synaptic cleft to interact with glutamate receptors found on the dendrites of RGCs. Glutamate receptors are divided into two main classes: ionotropic and metabotropic. The ionotropic glutamate receptors are further divided into NMDA and non-NMDA subtypes. The non-NMDA receptors are also known as AMPAr and Kainate receptors. NMDA receptors are known for their ability to be highly permeable to Ca2+ ion influx once they are activated. Typically NMDA receptors need both glutamate and glycine to be activated. However, NMDA receptors are subject to a Mg2+ blockade preventing calcium ion influx when the membrane potential is at rest (-90 to -70 mV). This Mg2+ can only be removed from the NMDA receptor complex once the membrane potential of the dendrites reaches between -20 and -30 mV. (Mayer et al., 1984; Ozawa et al., 1998) The Mg2+ blockade is typically relieved by raising the membrane potential through the activation of non-NMDA receptors. The stimulation of these ionotropic receptors causes excitatory postsynaptic currents that then go to further activate voltage gated calcium channels (VGCCs). VGCCs are divided into two major classes of Ca2+ channels based upon the membrane potential that opens them. There are low-voltage activated (LVA) and high-voltage activated (HVA) channels. These channels can be further divided into T-type which is the LVA and L-, N-, P/Q, and Rtype which are all HVA. Of the VGCCs, L-type is the one that is associated with calciummediated neuronal injury because of the prolong calcium influx that occurs when this channel is activated (Mark et al., 2001). Additionally, prolonged stimulation of VGCCs and NMDA channels has been shown in cortical neurons to suppress mitochondrial movement

the retina(A) and a representative retina flat mount (B).

nasal and temporal

in the dendrites (Li et al., 2004).

**A B**

chemical compounds which have the ability to activate pro-survival or inhibit pro-apoptotic pathways, downstream to NTs. It is also possible to deliver viral constructs or siRNAs to the retina: however, genetic manipulation of human cells always represents a potential biohazard issue. The other new method for sustained delivery of glaucoma medication involves incorporation of the drug into a punctal plug. This method is already used for patients suffering from dry eye syndrome. Another approach is usage of solid lipid nanoparticles loaded with neuroprotective drugs. Researchers have reported promising results from experiments using laboratory-created nanoparticles to deliver a glaucoma medication (Li et al., 2011). Investigations into this approach for treating glaucoma were in very early stages. This approach can also be used for NTs delivery. Animal experiments using nanoparticles demonstrated that they can actively migrate through the vitreous and neurosensory retinal layers, reaching the retinal pigment epithelium and choroid. This capability has proved to be useful particularly in treatment of retinal degeneration diseases. Nanotechnology can be used in ophthalmology to treat retinal degenerative disease with gene therapy, prosthetics, and regenerative nanomedicine (Zarbin et al., 2010). Another emerging technology for drug delivery to the eye is encapsulated cell technology (ECT). ECT has also been developed to treat diseases of the central nervous system and the eye (Tao et al., 2002). ECT could be applied to neurodegeneration treatment in glaucomatous eyes. This device can serve as a source of neurotrophic factors produced by encapsulated cells in the eye. Such an approach was already successfully used to delivery CNTF in a dog model of retinitis pigmentosa.

#### **3. Calcium channel blockers**

Calcium channel blockers (CCBs) have a therapeutic potential in treating glaucomatous optic neuropathy. However, their therapeutic potential as neuroprotectants has not yet been fully realized to treat glaucoma or other chronic neurodegenerative diseases. This section will discuss the importance of neuronal calcium signaling under normal physiological conditions. Secondly this section will then discuss the proposed hypothesis of calcium dysregulation in playing a key role in apoptosis, and the proposed mechanism of ischemiareperfusion that has been demonstrated to occur in some cases of glaucoma. Lastly, this section will then discuss CCBs as neuroprotective pharmaceutical agents, retinal vessel dilators, and IOP lowering agents.

Under physiological conditions, calcium is an important neuronal intracellular signaling molecule found at very low cytoplasmic concentrations (100 nM) under normal non-excited states (1-2 mM extracellularly). This low intracellular calcium concentration allows a strong inward electrochemical gradient, and facilitates the ability for calcium to be used as a quick communicator to activate and suppress a number of different genes and signaling pathways that are critical for neuronal survival, long term potentiation, and synaptic plasticity. Interestingly, it seems that not all calcium influx is considered equal. Different subset of neuronal signaling pathways can be activated depending on which channel is used to mediate calcium conduction inside neurons.

RGCs are the output neurons of the retina that conveys all the visual information obtained from the retina to the brain. Different synaptic inputs are received on the dendrites of RGCs from bipolar cells and amacrine cells. The normal flow of electrical potentials through the retina is initiated at the back of the retina starting from the photoreceptor cells. The electrical information then travels from photoreceptor cells to bipolar cells, and finally to RGCs.

chemical compounds which have the ability to activate pro-survival or inhibit pro-apoptotic pathways, downstream to NTs. It is also possible to deliver viral constructs or siRNAs to the retina: however, genetic manipulation of human cells always represents a potential biohazard issue. The other new method for sustained delivery of glaucoma medication involves incorporation of the drug into a punctal plug. This method is already used for patients suffering from dry eye syndrome. Another approach is usage of solid lipid nanoparticles loaded with neuroprotective drugs. Researchers have reported promising results from experiments using laboratory-created nanoparticles to deliver a glaucoma medication (Li et al., 2011). Investigations into this approach for treating glaucoma were in very early stages. This approach can also be used for NTs delivery. Animal experiments using nanoparticles demonstrated that they can actively migrate through the vitreous and neurosensory retinal layers, reaching the retinal pigment epithelium and choroid. This capability has proved to be useful particularly in treatment of retinal degeneration diseases. Nanotechnology can be used in ophthalmology to treat retinal degenerative disease with gene therapy, prosthetics, and regenerative nanomedicine (Zarbin et al., 2010). Another emerging technology for drug delivery to the eye is encapsulated cell technology (ECT). ECT has also been developed to treat diseases of the central nervous system and the eye (Tao et al., 2002). ECT could be applied to neurodegeneration treatment in glaucomatous eyes. This device can serve as a source of neurotrophic factors produced by encapsulated cells in the eye. Such an approach was already successfully used to delivery CNTF in a dog

Calcium channel blockers (CCBs) have a therapeutic potential in treating glaucomatous optic neuropathy. However, their therapeutic potential as neuroprotectants has not yet been fully realized to treat glaucoma or other chronic neurodegenerative diseases. This section will discuss the importance of neuronal calcium signaling under normal physiological conditions. Secondly this section will then discuss the proposed hypothesis of calcium dysregulation in playing a key role in apoptosis, and the proposed mechanism of ischemiareperfusion that has been demonstrated to occur in some cases of glaucoma. Lastly, this section will then discuss CCBs as neuroprotective pharmaceutical agents, retinal vessel

Under physiological conditions, calcium is an important neuronal intracellular signaling molecule found at very low cytoplasmic concentrations (100 nM) under normal non-excited states (1-2 mM extracellularly). This low intracellular calcium concentration allows a strong inward electrochemical gradient, and facilitates the ability for calcium to be used as a quick communicator to activate and suppress a number of different genes and signaling pathways that are critical for neuronal survival, long term potentiation, and synaptic plasticity. Interestingly, it seems that not all calcium influx is considered equal. Different subset of neuronal signaling pathways can be activated depending on which channel is used to

RGCs are the output neurons of the retina that conveys all the visual information obtained from the retina to the brain. Different synaptic inputs are received on the dendrites of RGCs from bipolar cells and amacrine cells. The normal flow of electrical potentials through the retina is initiated at the back of the retina starting from the photoreceptor cells. The electrical information then travels from photoreceptor cells to bipolar cells, and finally to RGCs.

model of retinitis pigmentosa.

**3. Calcium channel blockers**

dilators, and IOP lowering agents.

mediate calcium conduction inside neurons.

Glutamate is the main excitatory neurotransmitter that is released from photoreceptor cells and biopolar cells. Typically horizontal cells and amacrine cells modulate the electrical signal at the outer and inner plexiform layers respectively. Figure 7 shows various layers of the retina(A) and a representative retina flat mount (B).

Fig. 7. A. Organization of the retinal layers. Confocal microscopic image of a rat retina section. The different layers of the retina are indicated in the picture: Nerve fiber layer (NFL), Ganglion cell layer (GCL), Inner plexiform layer (IPL), Inner nuclear layer (INL), Outer plexiform layer (OPL), Outer nuclear layer (ONL) and Outer Segment (OS). B. Representative flat mount showing different areas of the retina including superior, inferior, nasal and temporal

Once glutamate is released from the axonal terminals of bipolar cells, it will migrate through the synaptic cleft to interact with glutamate receptors found on the dendrites of RGCs. Glutamate receptors are divided into two main classes: ionotropic and metabotropic. The ionotropic glutamate receptors are further divided into NMDA and non-NMDA subtypes. The non-NMDA receptors are also known as AMPAr and Kainate receptors. NMDA receptors are known for their ability to be highly permeable to Ca2+ ion influx once they are activated. Typically NMDA receptors need both glutamate and glycine to be activated. However, NMDA receptors are subject to a Mg2+ blockade preventing calcium ion influx when the membrane potential is at rest (-90 to -70 mV). This Mg2+ can only be removed from the NMDA receptor complex once the membrane potential of the dendrites reaches between -20 and -30 mV. (Mayer et al., 1984; Ozawa et al., 1998) The Mg2+ blockade is typically relieved by raising the membrane potential through the activation of non-NMDA receptors. The stimulation of these ionotropic receptors causes excitatory postsynaptic currents that then go to further activate voltage gated calcium channels (VGCCs). VGCCs are divided into two major classes of Ca2+ channels based upon the membrane potential that opens them. There are low-voltage activated (LVA) and high-voltage activated (HVA) channels. These channels can be further divided into T-type which is the LVA and L-, N-, P/Q, and Rtype which are all HVA. Of the VGCCs, L-type is the one that is associated with calciummediated neuronal injury because of the prolong calcium influx that occurs when this channel is activated (Mark et al., 2001). Additionally, prolonged stimulation of VGCCs and NMDA channels has been shown in cortical neurons to suppress mitochondrial movement in the dendrites (Li et al., 2004).

Neuroprotection in Glaucoma 155

Fig. 8. Calcium-induced apoptotic changes in neurons. Intracellular calcium in increased through the sequential actions of NMDA and voltage-dependent calcium channels. Elevated

downstream effects on substrates. Calcineurin activation promotes dephosphorylation of Bad which in turn initiates mitochondrial dysfunction by its interaction with Bcl2 or Bcl-XL. The disruption of mitochondria releases cytochrome c which activates the apoptotic cascade Calcium channel blockers (CCBs) are pharmaceutical agents geared at halting calcium influx across cellular membranes and decreasing intracellular calcium levels. These agents are widely used clinically to control patients suffering from benign essential hypertension, angina pectoris, cardiac arrhythmias (like atrial fibrillation and paroxysmal supraventricular tachycardia), and pulmonary hypertension. CCBs have been studied to treat many of the chronic neurological diseases afflicting individuals worldwide. CCBs could in theory act as neuroprotectants to help preserve neuronal viability, especially by halting the upstream activation of calcium sensitive apoptotic proteins (calcineurin and calpain) and can prevent permanent damage from the late stage activation of apoptosis (Loetscher et al., 2001). Many of the theories implicated in RGC death in glaucoma involve some form of calcium dysregulation. So if an appropriate CCB can be identified to treat RGCs vulnerable to apoptosis, then this pharmaceutical agent could halt the activation of many apoptotic pathways early on in the activation of the cell-death pathway. Additionally, CCBs have therapeutic potential in decreasing IOP and increasing retinal blood flow. Therefore, it is possible that a CCB treatment could act as a "silver bullet glaucoma therapy" by decreasing IOP, increasing retinal blood, and protecting RGCs by maintaining calcium homeostasis by acting as a neuroprotectant. The rest of this section will highlight CCBs as a pharmaceutical treatment to treat glaucoma as a neuroprotectant, retinal vessel vasodilator, and IOP

Ca2+ activates a number of factors including calpain and calcineurin which have

reducing molecule.

Under normal physiological conditions, calcium signaling inside neurons mediates a number of second messenger pathways. For example, when calcium influx occurs through neuronal L-type VGCCs that are encoded by the CaV1.2 and CaV1.3 pore-forming subunits, the channel has the ability to activate CREB, MEF, and NFAT that can lead to the expression of genes like *c-fos* and *bdnf* (Graef et al., 1999; Mao et al., 1999; Sheng et al., 1990; Morgan and Curran, 1986; Murphy et al., 1991; Zafra et al., 1990). Similarly, NMDA receptors expressing NR2A-containing glutamate receptors have demonstrated to promote long term potentiation through Ras-GRF2 and ERK MAP kinase activation (Flammer et al., 1994). It is evident that calcium signaling through ionotropic glutamate receptors and VGCCs are essential and needed for neuronal survival and functionality. However, one caveat in all of these studies is that the data has not been replicated in primary RGCs. So though, it can be assumed that RGCs are an excitatory neuron and probably do behave in a similar fashion to cortical excitatory neurons, there is not much information to determine if cell survival and long term potentiation pathways are also activated in RGCs when NMDA and L-type VGCCs are activated.

In chronic neurological disease processes, it is plausible that the beneficial effects that occur from neuronal calcium signaling are suppressed, and an overload of calcium causes activation of the apoptotic cascade. For example, normal stimulation of intrasynaptic NMDA receptors under physiological conditions causes activation of many pro-survival pathways which lead to phosphorylation of cAMP response element-binding protein (CREB) through activation of calmodulin-dependent protein (CaM) kinase pathway and Ras-extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (Hardingham et al., 2001; Wu et al., 2001; and Hardingham et al., 2001b). However, extrasynaptic NMDA stimulation suppresses CREB activation through the inactivation of Ras-ERK1/2 pathway (Hardingham et al., 2002; Hardingham et al., 2002b; and Ivanov et al. 2006). These opposing pathways are activated through similar receptors in different neuronal locations and demonstrate the importance of compartmentalization of calcium signaling in the neuron. When the same ionotropic calcium channel is stimulated, the location of that channel dictates the secondary pro-survival/pro-apoptotic pathways that are stimulated. It is clear from all these studies that basal calcium signaling is beneficial for the neuron, but overstimulation of these extrasynaptic NMDA receptors is detrimental for neuronal survival causing stimulation of apoptotic enzymes including calcineurin and calpain.

Calcineurin is a calmodulin-dependent serine-threonine phosphatase that activates Bad through dephosphorylation. This dephosphorylation causes BAD to dissociated from the inhibiting protein 14-3-3 and cause it to move into the mitochondrial outer membrane. Once Bad is on the outer mitochondrial members, it will bind to anti-apoptotic Bcl-2 or Bcl-XL and promote release of cytochrome c. (Wang et al., 1999; Heckman et al., 2006) Calcineurin activation and cytochrome c release has been linked with RGC death after optic nerve crush. (Huang et al., 2005) Lastly, RGC death has been shown to be attenuated in experimental models of optic nerve crush after treatment with a calcineurin inhibitor, FK506 (Huang et al., 2005).

Calpain is a Ca2+-dependent cysteine protease that is implicated in many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease (Nixon, 2003; Goll et al., 2003) Calpain activates calcineurin and transforms it into its constitutively activated form. Calpain activation has been detected in rat experimental glaucoma, (Huang et al., 2010) while its inactivation has demonstrated protection against excitotoxic neuronal cell death *in vitro* and *in vivo* (Wu et al., 2004).

Under normal physiological conditions, calcium signaling inside neurons mediates a number of second messenger pathways. For example, when calcium influx occurs through neuronal L-type VGCCs that are encoded by the CaV1.2 and CaV1.3 pore-forming subunits, the channel has the ability to activate CREB, MEF, and NFAT that can lead to the expression of genes like *c-fos* and *bdnf* (Graef et al., 1999; Mao et al., 1999; Sheng et al., 1990; Morgan and Curran, 1986; Murphy et al., 1991; Zafra et al., 1990). Similarly, NMDA receptors expressing NR2A-containing glutamate receptors have demonstrated to promote long term potentiation through Ras-GRF2 and ERK MAP kinase activation (Flammer et al., 1994). It is evident that calcium signaling through ionotropic glutamate receptors and VGCCs are essential and needed for neuronal survival and functionality. However, one caveat in all of these studies is that the data has not been replicated in primary RGCs. So though, it can be assumed that RGCs are an excitatory neuron and probably do behave in a similar fashion to cortical excitatory neurons, there is not much information to determine if cell survival and long term potentiation pathways are also activated in RGCs when NMDA and L-type

In chronic neurological disease processes, it is plausible that the beneficial effects that occur from neuronal calcium signaling are suppressed, and an overload of calcium causes activation of the apoptotic cascade. For example, normal stimulation of intrasynaptic NMDA receptors under physiological conditions causes activation of many pro-survival pathways which lead to phosphorylation of cAMP response element-binding protein (CREB) through activation of calmodulin-dependent protein (CaM) kinase pathway and Ras-extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (Hardingham et al., 2001; Wu et al., 2001; and Hardingham et al., 2001b). However, extrasynaptic NMDA stimulation suppresses CREB activation through the inactivation of Ras-ERK1/2 pathway (Hardingham et al., 2002; Hardingham et al., 2002b; and Ivanov et al. 2006). These opposing pathways are activated through similar receptors in different neuronal locations and demonstrate the importance of compartmentalization of calcium signaling in the neuron. When the same ionotropic calcium channel is stimulated, the location of that channel dictates the secondary pro-survival/pro-apoptotic pathways that are stimulated. It is clear from all these studies that basal calcium signaling is beneficial for the neuron, but overstimulation of these extrasynaptic NMDA receptors is detrimental for neuronal survival causing stimulation of

Calcineurin is a calmodulin-dependent serine-threonine phosphatase that activates Bad through dephosphorylation. This dephosphorylation causes BAD to dissociated from the inhibiting protein 14-3-3 and cause it to move into the mitochondrial outer membrane. Once Bad is on the outer mitochondrial members, it will bind to anti-apoptotic Bcl-2 or Bcl-XL and promote release of cytochrome c. (Wang et al., 1999; Heckman et al., 2006) Calcineurin activation and cytochrome c release has been linked with RGC death after optic nerve crush. (Huang et al., 2005) Lastly, RGC death has been shown to be attenuated in experimental models of optic nerve crush after treatment with a calcineurin inhibitor, FK506 (Huang et al.,

Calpain is a Ca2+-dependent cysteine protease that is implicated in many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease (Nixon, 2003; Goll et al., 2003) Calpain activates calcineurin and transforms it into its constitutively activated form. Calpain activation has been detected in rat experimental glaucoma, (Huang et al., 2010) while its inactivation has demonstrated protection against excitotoxic neuronal

VGCCs are activated.

2005).

apoptotic enzymes including calcineurin and calpain.

cell death *in vitro* and *in vivo* (Wu et al., 2004).

Fig. 8. Calcium-induced apoptotic changes in neurons. Intracellular calcium in increased through the sequential actions of NMDA and voltage-dependent calcium channels. Elevated Ca2+ activates a number of factors including calpain and calcineurin which have downstream effects on substrates. Calcineurin activation promotes dephosphorylation of Bad which in turn initiates mitochondrial dysfunction by its interaction with Bcl2 or Bcl-XL. The disruption of mitochondria releases cytochrome c which activates the apoptotic cascade

Calcium channel blockers (CCBs) are pharmaceutical agents geared at halting calcium influx across cellular membranes and decreasing intracellular calcium levels. These agents are widely used clinically to control patients suffering from benign essential hypertension, angina pectoris, cardiac arrhythmias (like atrial fibrillation and paroxysmal supraventricular tachycardia), and pulmonary hypertension. CCBs have been studied to treat many of the chronic neurological diseases afflicting individuals worldwide. CCBs could in theory act as neuroprotectants to help preserve neuronal viability, especially by halting the upstream activation of calcium sensitive apoptotic proteins (calcineurin and calpain) and can prevent permanent damage from the late stage activation of apoptosis (Loetscher et al., 2001). Many of the theories implicated in RGC death in glaucoma involve some form of calcium dysregulation. So if an appropriate CCB can be identified to treat RGCs vulnerable to apoptosis, then this pharmaceutical agent could halt the activation of many apoptotic pathways early on in the activation of the cell-death pathway. Additionally, CCBs have therapeutic potential in decreasing IOP and increasing retinal blood flow. Therefore, it is possible that a CCB treatment could act as a "silver bullet glaucoma therapy" by decreasing IOP, increasing retinal blood, and protecting RGCs by maintaining calcium homeostasis by acting as a neuroprotectant. The rest of this section will highlight CCBs as a pharmaceutical treatment to treat glaucoma as a neuroprotectant, retinal vessel vasodilator, and IOP reducing molecule.

Neuroprotection in Glaucoma 157

researchers have speculated that patients suffering from normal tension glaucoma could be developing glaucomatous optic neuropathy because of a vasospastic syndrome (Flammer et al., 1987; Broadway and Drance 1998). Research studies have actually demonstrated that patients suffering from glaucoma are more prone to suffer from vasospastic episodes (Gasser and Flammer, 1991; Rojanapongpun and Drance, 1993; O'Brien 1998). In fact, in some glaucoma patients, improvements are seen in retinal circulation and visual field defects when patients are treated with CCBs (Flammer and Guthauser, 1987; Guthauser et

As mentioned above, CCBs have the ability to block intracellular calcium influx, which can lead to relaxation of vascular smooth muscle and enable enhanced blood flow to perfuse certain organs. There are numerous studies that have been conducted in looking at the effects of nifedipine, nicardipine, verapamil, nimodipine, nilvadipine, and lomerizine on ocular blood flow and their abilities to counteract retinal vasospasm. In a prospective clinical trial, Kitazawa et al. (1989) treated 25 patients suffering from normal tension glaucoma with oral nifedipine for 6 months and was able to demonstrate improved visual fields. However, another study performed by Harris et al. (1997) showed that 6-month treatment with oral nifedipine in 21 patients failed to demonstrated significant difference in visual field and spatal contrast sensitivity. Another prospective study performed on patients with open angle glaucoma showed that a 3 month treatment with nifedipine had no affect on improving visual fields compared with the control group (Rainer et al., 2001). In contrast, nimodipine has demonstrated in multiple prospective clinical trials to improve visual function in normal tension glaucoma patients (Bose et al., 1995; Piltz et al., 1998; Boehm et al., 2003; Luksch et al., 2005) How some of these CCBs demonstrated improvement in visual function in patients suffering from glaucoma is unknown, but perhaps it could have been

through both a vasodilator affect, and a direct neuroprotective effect on the RGCs.

A final therapeutic target for CCBs is their ability to lower IOP when given topically. The mechanism of action of CCBs in lowering IOP is still controversial.  Ciliary epithelial cells also have DHPsensitive, VGCCs (Farahbakhsh et al., 1994). CCBs act by decreasing in-flow through its effects on ciliary epithelial cells, or improve outflow through its effects on the TM cells. Out of all the therapies used to treat glaucoma, CCBs have the capability to lower IOP while also increasing retinal blood flow and protecting RGCs from pathological influxes of cytoplasmic

Though there is a lot of evidence correlating pathological influx of cytoplasmic calcium with RGC death, the fact of the matter is that there are probably many pathological pathways acting in concert with one another to elicit RGC apoptosis (Qu et al., 2010). For example, astrocytes and retinal glial cells can fail to take up glutamate from the excess glutamate that is being released from damaged RGCs in glaucoma (Adachi et al., 1998; Danbolt, 2001) Therefore, excitoxicity then can cause pathological influx of calcium ions through overactivation of NMDA receptors and VGCCs. This elevation of calcium ions can not only cause activation of calcium specific apoptotic enzymes, but also generate large amounts of free radicals which can in-turn cause oxidative stress (Tezel, 2006). So therefore, it is not only important to investigate potential therapeutic targets that are geared at protecting RGCs from cell death caused by glaucomatous optic neuropathy insults, but it is just as important to understand basic cellular and molecular mechanisms underlying neuronal cell death in

al., 1988).

calcium.

glaucoma.

The use of CCBs to treat glaucoma as a neuroprotectant is based upon the assumption that two fundamental molecular hypothesizes implicated in RGC death in glaucoma are correct. These two hypothesizes are that glutamate excitotoxicity exist, and that calcium dysregulation occurs and activates apoptotic enzymes in glaucoma. The debate over glutamate excitotoxicity as a pathological correlate to RGC death in glaucoma is addressed in the glutamate excitotoxicity portion of this chapter. There does appear to be evidence, as mentioned above, that calcium dysregulation does occur prior to RGC death. Drugs that are geared at blocking calcium ion influx mainly target two classes of ion channels, NMDA receptors and L-type VGCCs. The section on excitotoxicity will touch upon treatments that have shown neuroprotective potential through the blockade of NMDA receptors.

Of the drugs that have been developed and used to treat human pathological conditions, there are three classes of drugs geared at blocking L-type VGCCs. These three main classes are the phenylalkylamine (PAA), or verapamil-like CCBs, the benzothiazepine (BTZ), or diltiazem-like CCBs, and the dihydropyridine (DHP), or nifedipine-like CCBs (Araie and Mayana, 2010). In animal studies, intraperitoneal injections of nifedipine showed neuroprotection and improved b-wave amplitude when rats received retinal ischemic damage (Crosson et al., 1990) Lomerizine is another L-type and T-type CCB that has demonstrated to have neuroprotective effects on ischemic retinal neurons in both *in vitro*  and *in vivo* (Toriu et al., 2000). In primary RGC cultures exposed to hypoxic conditions (5% normal partical pressure), iganidipine, nimodipine, and lomerizine demonstrated robust RGC protection (Yamada et al., 2006; Chen et al., 2007).

Another pharmaceutical agent that has demonstrated neuroprotection to RGCs by blocking calcium currents is betaxolol, a β1-adrenoceptor antagonists (Araie and Mayana, 2010). This molecule has demonstrated to have binding affinity to L-type VGCCs and NMDA, and has been shown to decrease calcium influx through the cellular plasma membrane. (Melena et al., 1999; Bessho et al., 1991; Hester et al., 1994; Hoste and Sis, 1998; Setoguchi et al., 1995; Dong et al., 2006; Nagata et al., 2008) Considering the potential that blocking L-type VGCCs has demonstrated as being a neuroprotectant as described above, their may be therapeutic potential for treating patients afflicted with glaucoma with betaxolol as well. Betaxolol may act as an IOP lowering agent and as a neuroprotectant by blocking pathological influxes of calcium through L-type VGCCs. (Hirooka et al., 2000) Topical application of betaxolol has also been reported to induce expression of BDNF in the rat retina. (Wood et al., 2001). In vivo experiments also demonstrated protection through the attenuation of retinal damage to rabbits and rats subjected to ischemic insult (Wood et al., 2001; Wood et al., 2003; Osborne et al., 1999; Osborne et al., 2004; Cheon et al., 2002) or to rat eyes injected with NMDA or kainic acid (Osborne et al., 1999; Cheon et al., 2006). However given betaxolol's L-type VGCC blocking effect, when this drug was tested next to timolol in a large comparative human clinical trial, there was no difference in disease progression between those patients taking either timolol or betaxolol (Watson et al., 2001; Araie et al., 2003). Lastly, in another human clinical trial, the conversion rate from ocular hypertension to glaucoma between betaxolol and placebo was not attenuated between the two treatment groups (Kamal et al., 2003).

The predominant theory of what precipitates the cascade of RGC death in glaucoma is the mechanical compression theory highlighted above. However, another theory of retinal ischemia reperfusion has been put forth to account for RGC loss as a consequence of insufficient retinal blood flow (Flammer, 1994). The retina receives its blood supply from the central retinal artery which is a branch from the ophthalmic artery (Olver, 1998). Insufficient blood flow to the retina is able to produce glaucomatous-like visual field defects, and

The use of CCBs to treat glaucoma as a neuroprotectant is based upon the assumption that two fundamental molecular hypothesizes implicated in RGC death in glaucoma are correct. These two hypothesizes are that glutamate excitotoxicity exist, and that calcium dysregulation occurs and activates apoptotic enzymes in glaucoma. The debate over glutamate excitotoxicity as a pathological correlate to RGC death in glaucoma is addressed in the glutamate excitotoxicity portion of this chapter. There does appear to be evidence, as mentioned above, that calcium dysregulation does occur prior to RGC death. Drugs that are geared at blocking calcium ion influx mainly target two classes of ion channels, NMDA receptors and L-type VGCCs. The section on excitotoxicity will touch upon treatments that

Of the drugs that have been developed and used to treat human pathological conditions, there are three classes of drugs geared at blocking L-type VGCCs. These three main classes are the phenylalkylamine (PAA), or verapamil-like CCBs, the benzothiazepine (BTZ), or diltiazem-like CCBs, and the dihydropyridine (DHP), or nifedipine-like CCBs (Araie and Mayana, 2010). In animal studies, intraperitoneal injections of nifedipine showed neuroprotection and improved b-wave amplitude when rats received retinal ischemic damage (Crosson et al., 1990) Lomerizine is another L-type and T-type CCB that has demonstrated to have neuroprotective effects on ischemic retinal neurons in both *in vitro*  and *in vivo* (Toriu et al., 2000). In primary RGC cultures exposed to hypoxic conditions (5% normal partical pressure), iganidipine, nimodipine, and lomerizine demonstrated robust

Another pharmaceutical agent that has demonstrated neuroprotection to RGCs by blocking calcium currents is betaxolol, a β1-adrenoceptor antagonists (Araie and Mayana, 2010). This molecule has demonstrated to have binding affinity to L-type VGCCs and NMDA, and has been shown to decrease calcium influx through the cellular plasma membrane. (Melena et al., 1999; Bessho et al., 1991; Hester et al., 1994; Hoste and Sis, 1998; Setoguchi et al., 1995; Dong et al., 2006; Nagata et al., 2008) Considering the potential that blocking L-type VGCCs has demonstrated as being a neuroprotectant as described above, their may be therapeutic potential for treating patients afflicted with glaucoma with betaxolol as well. Betaxolol may act as an IOP lowering agent and as a neuroprotectant by blocking pathological influxes of calcium through L-type VGCCs. (Hirooka et al., 2000) Topical application of betaxolol has also been reported to induce expression of BDNF in the rat retina. (Wood et al., 2001). In vivo experiments also demonstrated protection through the attenuation of retinal damage to rabbits and rats subjected to ischemic insult (Wood et al., 2001; Wood et al., 2003; Osborne et al., 1999; Osborne et al., 2004; Cheon et al., 2002) or to rat eyes injected with NMDA or kainic acid (Osborne et al., 1999; Cheon et al., 2006). However given betaxolol's L-type VGCC blocking effect, when this drug was tested next to timolol in a large comparative human clinical trial, there was no difference in disease progression between those patients taking either timolol or betaxolol (Watson et al., 2001; Araie et al., 2003). Lastly, in another human clinical trial, the conversion rate from ocular hypertension to glaucoma between betaxolol and placebo was not attenuated between the two treatment groups (Kamal et al., 2003). The predominant theory of what precipitates the cascade of RGC death in glaucoma is the mechanical compression theory highlighted above. However, another theory of retinal ischemia reperfusion has been put forth to account for RGC loss as a consequence of insufficient retinal blood flow (Flammer, 1994). The retina receives its blood supply from the central retinal artery which is a branch from the ophthalmic artery (Olver, 1998). Insufficient blood flow to the retina is able to produce glaucomatous-like visual field defects, and

have shown neuroprotective potential through the blockade of NMDA receptors.

RGC protection (Yamada et al., 2006; Chen et al., 2007).

researchers have speculated that patients suffering from normal tension glaucoma could be developing glaucomatous optic neuropathy because of a vasospastic syndrome (Flammer et al., 1987; Broadway and Drance 1998). Research studies have actually demonstrated that patients suffering from glaucoma are more prone to suffer from vasospastic episodes (Gasser and Flammer, 1991; Rojanapongpun and Drance, 1993; O'Brien 1998). In fact, in some glaucoma patients, improvements are seen in retinal circulation and visual field defects when patients are treated with CCBs (Flammer and Guthauser, 1987; Guthauser et al., 1988).

As mentioned above, CCBs have the ability to block intracellular calcium influx, which can lead to relaxation of vascular smooth muscle and enable enhanced blood flow to perfuse certain organs. There are numerous studies that have been conducted in looking at the effects of nifedipine, nicardipine, verapamil, nimodipine, nilvadipine, and lomerizine on ocular blood flow and their abilities to counteract retinal vasospasm. In a prospective clinical trial, Kitazawa et al. (1989) treated 25 patients suffering from normal tension glaucoma with oral nifedipine for 6 months and was able to demonstrate improved visual fields. However, another study performed by Harris et al. (1997) showed that 6-month treatment with oral nifedipine in 21 patients failed to demonstrated significant difference in visual field and spatal contrast sensitivity. Another prospective study performed on patients with open angle glaucoma showed that a 3 month treatment with nifedipine had no affect on improving visual fields compared with the control group (Rainer et al., 2001). In contrast, nimodipine has demonstrated in multiple prospective clinical trials to improve visual function in normal tension glaucoma patients (Bose et al., 1995; Piltz et al., 1998; Boehm et al., 2003; Luksch et al., 2005) How some of these CCBs demonstrated improvement in visual function in patients suffering from glaucoma is unknown, but perhaps it could have been through both a vasodilator affect, and a direct neuroprotective effect on the RGCs.

A final therapeutic target for CCBs is their ability to lower IOP when given topically. The mechanism of action of CCBs in lowering IOP is still controversial.  Ciliary epithelial cells also have DHPsensitive, VGCCs (Farahbakhsh et al., 1994). CCBs act by decreasing in-flow through its effects on ciliary epithelial cells, or improve outflow through its effects on the TM cells. Out of all the therapies used to treat glaucoma, CCBs have the capability to lower IOP while also increasing retinal blood flow and protecting RGCs from pathological influxes of cytoplasmic calcium.

Though there is a lot of evidence correlating pathological influx of cytoplasmic calcium with RGC death, the fact of the matter is that there are probably many pathological pathways acting in concert with one another to elicit RGC apoptosis (Qu et al., 2010). For example, astrocytes and retinal glial cells can fail to take up glutamate from the excess glutamate that is being released from damaged RGCs in glaucoma (Adachi et al., 1998; Danbolt, 2001) Therefore, excitoxicity then can cause pathological influx of calcium ions through overactivation of NMDA receptors and VGCCs. This elevation of calcium ions can not only cause activation of calcium specific apoptotic enzymes, but also generate large amounts of free radicals which can in-turn cause oxidative stress (Tezel, 2006). So therefore, it is not only important to investigate potential therapeutic targets that are geared at protecting RGCs from cell death caused by glaucomatous optic neuropathy insults, but it is just as important to understand basic cellular and molecular mechanisms underlying neuronal cell death in glaucoma.

Neuroprotection in Glaucoma 159

glutamate and similar agonists. Metabotropic receptors are G-protein coupled receptors which couple ligand binding to intracellular signal transduction mechanisms mediated by a variety of second messengers including cAMP and intracellular calcium. Excitotoxicity is mediated by ionotropic receptors which can be characterized into various subtypes according to the type of the selective agonist including, N-methyl D-aspartate (NMDA), αamino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate. These agonists are not naturally occurring, but have a structural resemblance to glutamate. Glutamate binds to and activates all three classes of receptors namely, NMDA, AMPA and kainate receptors. NMDA receptor activation is important for synaptic plasticity which plays a key role in memory and learning. However, overstimulation of NMDA receptors contributes to

The NMDA receptor has a tetrameric structures composed of two subunits of NR1 and NR2 subunits (Figure 10). There are four subtypes of NR2 subunits called NR2A, NR2B, NR2C and NR2D. Other related subunits including NR3 and NR4 have inhibitory effect on receptor activity. Activation of the NMDA receptor requires binding of two molecules of glutamate and two molecules of glycine which acts as a co-agonist. The AMPA receptor (AMPAr) also functions as a tetramer comprised of four different types of subunits including GluR1 to GluR4. Most AMPA receptors have a structure comprising of a combination of a dimer of GluR2 with a dimer of either GluR1, GluR3 or GluR4 (Figure 10). Each subunit of the AMPA receptor has a binding site for glutamate. Binding of glutamate to AMPA receptors causes an opening of the ion channel leading to an influx of sodium ions. AMPA and kainate receptors play an important role in facilitating rapid excitatory neurotransmission by rapid conduction of Na+ ions. AMPA receptors in the retina are also permeable to Ca2+ ions. Electrical stimulation of a presynaptic neuron causes glutamate release which activate AMPA receptors in the post-synaptic neuron. Activation of AMPAr causes depolarization of the post-synaptic neuron. However glutamate binding to NMDA receptors in weakly depolarized postsynaptic neurons is not sufficient to trigger activation of the receptors. NMDA receptors possess a high conductance Ca2+ channels which in normal resting state have a magnesium block that prevents activation of the channel. However, high frequency activation of the AMPAr (due to arrival of a train of nerve impulses) causes a release of the magnesium block of the NMDA receptors producing an influx of calcium ions. AMPArs have a dual role in neuroprotection depending upon their spatiotemporal pattern of expression. Increased expression of GluR1 in neurons has been demonstrated to facilitate dendrite outgrowth and synaptogenesis, while increased expression of GluR2 preserves existing dendritic arbors (Prithiviraj et al., 2008). This dynamic receptor moves into and out of the plasma membrane, and when the AMPAr complex is comprised of both the GluR1 and GluR2 subunits, it is correlated with

synaptogenesis and long term potentiation (LTP) (Malinow and Malenka, 2002).

Under pathological conditions, when neurons are under stress, AMPAr is also implicated in cell death by excitotoxicity through the increase permeability of AMPAr to calcium ions by the endocytosis of GluR2 (Beattie et al., 2010). During elevation of IOP in a rodent model, GluR2 expression in the dying RGCs demonstrated a decreased level of expression, implying that this decrease level of GluR2 expression made the RGCs more susceptible to calcium overload through the increased permeability of calcium through the AMPArs. Typically AMPArs are impervious to calcium ion influx when GluR2 is associated with the AMPAr complex on the plasma membrane. So how can increased AMPAr expression be implicated both as a neuroprotective, neurotrophic physiological cellular process, and also

elevation of intracellular calcium leading to neuronal injury.

#### **4. Glutamate excitotoxicity**

Excitotoxicity is a process by which excitatory amino acids such as glutamic acid (glutamate) and aspartic acid produce overstimulation of their receptors leading to neurotoxicity and/or neurodegeneration. Glutamate is a major excitatory neurotransmitter both in the brain and in the retina. The excitatory neurotransmitters in the brain include glutamate and aspartate, while the inhibitory neurotransmitters include GABA, glycine and taurine. In the retina, glutamate is the primary neurotransmitter that is involved in the visual transduction pathway. Glutamate is an α-amino acid containing a second carboxylic acid (-COOH) group attached to the γ-carbon atom. In the CNS, glutamate does not cross the blood brain barrier, hence in neurons, glutamate is made from α-ketoglutarate, an intermediate of the TCA cycle. Another source of glutamate is the conversion of glutamine obtained from glial cells to glutamate within neurons. This cycle is described in Figure 9.

Fig. 9. The Glutamate-Glutamine cycling between neurons and glia. Glutamate (GLU) is taken up by glial cells and converted to glutamine (GLN) by the enzyme glutamine synthase (GS). Glutamine is transported by the action of excitatory amino acid transporters (EAATs) back to the neurons where it is converted back to glutamate by the enzyme glutaminase (GLNase)

Glutamate is generated by the enzyme, glutaminase, in the endoplasmic reticulum, packaged in the golgi apparatus into membrane-bound vesicles and transported down the axon by anterograde axonal transport on microtubules to the synaptic junctions. The membranes of the vesicles merge with the synaptic membrane and glutamate is released by exocytosis into the synaptic space. Upon release into the synapse, glutamate binds to glutamate receptors in the post-synaptic membranes. There are two principal classes of glutamate receptors: ionotropic and metabotropic receptors. Ionotropic receptors are ligandgated ion channels which produce an influx of calcium and sodium ions upon binding to

Excitotoxicity is a process by which excitatory amino acids such as glutamic acid (glutamate) and aspartic acid produce overstimulation of their receptors leading to neurotoxicity and/or neurodegeneration. Glutamate is a major excitatory neurotransmitter both in the brain and in the retina. The excitatory neurotransmitters in the brain include glutamate and aspartate, while the inhibitory neurotransmitters include GABA, glycine and taurine. In the retina, glutamate is the primary neurotransmitter that is involved in the visual transduction pathway. Glutamate is an α-amino acid containing a second carboxylic acid (-COOH) group attached to the γ-carbon atom. In the CNS, glutamate does not cross the blood brain barrier, hence in neurons, glutamate is made from α-ketoglutarate, an intermediate of the TCA cycle. Another source of glutamate is the conversion of glutamine obtained from glial cells

Fig. 9. The Glutamate-Glutamine cycling between neurons and glia. Glutamate (GLU) is taken up by glial cells and converted to glutamine (GLN) by the enzyme glutamine synthase (GS). Glutamine is transported by the action of excitatory amino acid transporters (EAATs) back to the neurons where it is converted back to glutamate by the enzyme glutaminase

Glutamate is generated by the enzyme, glutaminase, in the endoplasmic reticulum, packaged in the golgi apparatus into membrane-bound vesicles and transported down the axon by anterograde axonal transport on microtubules to the synaptic junctions. The membranes of the vesicles merge with the synaptic membrane and glutamate is released by exocytosis into the synaptic space. Upon release into the synapse, glutamate binds to glutamate receptors in the post-synaptic membranes. There are two principal classes of glutamate receptors: ionotropic and metabotropic receptors. Ionotropic receptors are ligandgated ion channels which produce an influx of calcium and sodium ions upon binding to

to glutamate within neurons. This cycle is described in Figure 9.

**4. Glutamate excitotoxicity**

(GLNase)

glutamate and similar agonists. Metabotropic receptors are G-protein coupled receptors which couple ligand binding to intracellular signal transduction mechanisms mediated by a variety of second messengers including cAMP and intracellular calcium. Excitotoxicity is mediated by ionotropic receptors which can be characterized into various subtypes according to the type of the selective agonist including, N-methyl D-aspartate (NMDA), αamino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate. These agonists are not naturally occurring, but have a structural resemblance to glutamate. Glutamate binds to and activates all three classes of receptors namely, NMDA, AMPA and kainate receptors. NMDA receptor activation is important for synaptic plasticity which plays a key role in memory and learning. However, overstimulation of NMDA receptors contributes to elevation of intracellular calcium leading to neuronal injury.

The NMDA receptor has a tetrameric structures composed of two subunits of NR1 and NR2 subunits (Figure 10). There are four subtypes of NR2 subunits called NR2A, NR2B, NR2C and NR2D. Other related subunits including NR3 and NR4 have inhibitory effect on receptor activity. Activation of the NMDA receptor requires binding of two molecules of glutamate and two molecules of glycine which acts as a co-agonist. The AMPA receptor (AMPAr) also functions as a tetramer comprised of four different types of subunits including GluR1 to GluR4. Most AMPA receptors have a structure comprising of a combination of a dimer of GluR2 with a dimer of either GluR1, GluR3 or GluR4 (Figure 10). Each subunit of the AMPA receptor has a binding site for glutamate. Binding of glutamate to AMPA receptors causes an opening of the ion channel leading to an influx of sodium ions. AMPA and kainate receptors play an important role in facilitating rapid excitatory neurotransmission by rapid conduction of Na+ ions. AMPA receptors in the retina are also permeable to Ca2+ ions. Electrical stimulation of a presynaptic neuron causes glutamate release which activate AMPA receptors in the post-synaptic neuron. Activation of AMPAr causes depolarization of the post-synaptic neuron. However glutamate binding to NMDA receptors in weakly depolarized postsynaptic neurons is not sufficient to trigger activation of the receptors. NMDA receptors possess a high conductance Ca2+ channels which in normal resting state have a magnesium block that prevents activation of the channel. However, high frequency activation of the AMPAr (due to arrival of a train of nerve impulses) causes a release of the magnesium block of the NMDA receptors producing an influx of calcium ions. AMPArs have a dual role in neuroprotection depending upon their spatiotemporal pattern of expression. Increased expression of GluR1 in neurons has been demonstrated to facilitate dendrite outgrowth and synaptogenesis, while increased expression of GluR2 preserves existing dendritic arbors (Prithiviraj et al., 2008). This dynamic receptor moves into and out of the plasma membrane, and when the AMPAr complex is comprised of both the GluR1 and GluR2 subunits, it is correlated with synaptogenesis and long term potentiation (LTP) (Malinow and Malenka, 2002).

Under pathological conditions, when neurons are under stress, AMPAr is also implicated in cell death by excitotoxicity through the increase permeability of AMPAr to calcium ions by the endocytosis of GluR2 (Beattie et al., 2010). During elevation of IOP in a rodent model, GluR2 expression in the dying RGCs demonstrated a decreased level of expression, implying that this decrease level of GluR2 expression made the RGCs more susceptible to calcium overload through the increased permeability of calcium through the AMPArs. Typically AMPArs are impervious to calcium ion influx when GluR2 is associated with the AMPAr complex on the plasma membrane. So how can increased AMPAr expression be implicated both as a neuroprotective, neurotrophic physiological cellular process, and also

Neuroprotection in Glaucoma 161

traumatic brain injury, stoke, epilepsy, and also in various neurodegenerative diseases including Huntington disease, amyotrophic lateral sclerosis, AIDS dementia. Elevation of intracellular calcium is thought to be the primary mechanism leading to excitotoxicity by glutamate. The intracellular calcium levels are maintained at low levels (typically 100 nM in most cell types), while extracellular calcium concentrations are much higher (1 to 2 mM). NMDA receptors activation cause calcium influx into cells which produces membrane depolarization and this activates voltage-dependent calcium channels. Opening of these channels amplifies the calcium response, thereby exacerbating calcium overload in the cells. Calcium levels homeostasis maintained by a variety of calcium pumps and antiporters in the plasma membrane, endoplasmic reticulum and mitochondria. Ca2+-ATPases use energy inherent in ATP hydrolysis to pump calcium ions across the plasma membrane by active transport. These pumps have high affinity but low capacity, pumping out one Ca2+ ion for each molecule of ATP hydrolyzed. Sodium calcium exchangers act as antiporters use the sodium gradient across the plasma membrane to exchange calcium ions for sodium ions. However under conditions of ischemia, due to poor energy (ATP) production, the sodium gradients across cell membranes are decreased thereby affect the ability antiporters to extrude Ca2+ ions (Figure 11). All these factors contribute to elevation of cytosolic calcium. Increase in cytosolic calcium activates a variety of signaling molecules that influence the fate of cell survival. For example calcium binds to calmodulin and activate CaM kinase II which phosphorylates a variety of substrates, various enzymes and transcription factors. Calcium activates calpains which degrades essential cellular proteins. Calcium also activates

One of the key targets of elevated intracellular calcium is the mitochondria, which undergoes changes that could lead to opening of the permeability transition pore (Nickells, 2004). The mitochondrial calcium antiporter is a low affinity high capacity calcium transporter that pumps calcium ions into the mitochondria upon elevation of cytoplasmic calcium. Ca2+ build up in the mitochondria produces mitochondrial swelling by dissipating the voltage gradient between the outer and inner mitochondrial membrane. The inner mitochondrial membrane is flexible and thrown into multiple folds called cristae, and is therefore able to withstand the increase in volume. However the outer mitochondria membrane is unable to accommodate the increase in volume and ruptures, leading to release of cytochrome c from the mitochondria. The released cytochrome c forms a complex with apoptotic protein activating factor-1 (APAF-1) and caspase 9 to form the apoptosome which in turns activates the caspases which cleave a variety of structural and regulatory

Excitatory amino acid transporters (EAATs): After glutamate is released into the synaptic cleft, it is not degraded since there are no extracellular enzymes for its degradation. Glutamatergic transmission is terminated by rapid uptake of glutamate by a variety of specific glutamate transporters which are called excitatory amino acid transporters (EAATs) (Beretta et al., 2003). There are several classes of EAATs including EAAT1 (GLAST), EAAT2 (GLT), EAAT3 (EAAC), EAAT4 and EAAT5 (expressed mainly in the retina) each of which is encoded by distinct genes (Beretta et al., 2003). EAAT1 expression has been observed mainly in astrocytes throughout the CNS. EAAT1 is a plasma membrane bound protein and rarely detected in the cytoplasm. EAAT2 is also a plasma membrane protein expressed in astrocytes in various cerebral areas. EAAT3 is a major excitatory amino acid transporter in the neurons and highly expressed in hippocampus, cerebellum, and basal ganglia. EAAT4 expressed has been observed both in the cytoplasm and plasma membrane. EAAT4 is

endonucleases and promotes cleavage of genomic DNA.

protein thereby leading to apoptotic death of cells.

associated with increased neuronal excitotoxicity when neurons are under pathological stress? The answer appears to be in the ability to maintain GluR2 expression in the AMPAr complex in order to impede calcium ion influx through AMPAr on the plasma membrane while maintaining the beneficial role that AMPAr (GluR1/GluR2) plays in promoting dendritic outgrowth and promoting LTP (Gainey et al., 2009). Kainate receptors also have a tetrameric structure comprising of a combination of GluR5, GluR6 and GluR7 subunits. The role of kainite receptors is not as well understood as the NMDA and AMPA receptors (Figure 10).

Fig. 10. Classes of glutamate receptors and transporters. Glutamate acts by binding to three main classes of receptors including NMDA (A), AMPA (B) and Kainate receptors (C) which are ligand-gated ion channels. All the glutamate receptors are permeable to sodium, and calcium ions. NMDA receptor is a tetramer comprising of two subunits of NR1 and NR2. AMPA receptor contains four different types of subunits called GluR 1 to GluR4. Kainate receptors are also tetrameric in structure and their subunits are named KA1 and KA2 and GluR5 to GluR7. EAAT is a excitatory glutamate transporter which is a high affinity sodium dependent membrane-bound carrier protein having a ion channel-like structure

While glutamate is the primary neurotransmitter in the vertical pathway of the retina (from photoreceptor to bipolar cells to ganglion cells), abnormal increase in glutamate has been thought contribute to retinal injury. One of the earliest observations describing glutamate excitotoxicity was made by Hayashi in 1954 who observed seizure activities in brain after administration of glutamate to neonatal mice. Subsequently, Lucas and Newhouse (1957) reported that postnatal mice fed with monosodium glutamate show loss of inner retinal neurons. These observations were the basis of "glutamate excitotoxicity" hypothesis in glaucoma. Excitotoxicity has also been shown to occur in clinical conditions including

associated with increased neuronal excitotoxicity when neurons are under pathological stress? The answer appears to be in the ability to maintain GluR2 expression in the AMPAr complex in order to impede calcium ion influx through AMPAr on the plasma membrane while maintaining the beneficial role that AMPAr (GluR1/GluR2) plays in promoting dendritic outgrowth and promoting LTP (Gainey et al., 2009). Kainate receptors also have a tetrameric structure comprising of a combination of GluR5, GluR6 and GluR7 subunits. The role of kainite receptors is not as well understood as the NMDA and AMPA receptors

Fig. 10. Classes of glutamate receptors and transporters. Glutamate acts by binding to three main classes of receptors including NMDA (A), AMPA (B) and Kainate receptors (C) which are ligand-gated ion channels. All the glutamate receptors are permeable to sodium, and calcium ions. NMDA receptor is a tetramer comprising of two subunits of NR1 and NR2. AMPA receptor contains four different types of subunits called GluR 1 to GluR4. Kainate receptors are also tetrameric in structure and their subunits are named KA1 and KA2 and GluR5 to GluR7. EAAT is a excitatory glutamate transporter which is a high affinity sodium

While glutamate is the primary neurotransmitter in the vertical pathway of the retina (from photoreceptor to bipolar cells to ganglion cells), abnormal increase in glutamate has been thought contribute to retinal injury. One of the earliest observations describing glutamate excitotoxicity was made by Hayashi in 1954 who observed seizure activities in brain after administration of glutamate to neonatal mice. Subsequently, Lucas and Newhouse (1957) reported that postnatal mice fed with monosodium glutamate show loss of inner retinal neurons. These observations were the basis of "glutamate excitotoxicity" hypothesis in glaucoma. Excitotoxicity has also been shown to occur in clinical conditions including

dependent membrane-bound carrier protein having a ion channel-like structure

(Figure 10).

traumatic brain injury, stoke, epilepsy, and also in various neurodegenerative diseases including Huntington disease, amyotrophic lateral sclerosis, AIDS dementia. Elevation of intracellular calcium is thought to be the primary mechanism leading to excitotoxicity by glutamate. The intracellular calcium levels are maintained at low levels (typically 100 nM in most cell types), while extracellular calcium concentrations are much higher (1 to 2 mM). NMDA receptors activation cause calcium influx into cells which produces membrane depolarization and this activates voltage-dependent calcium channels. Opening of these channels amplifies the calcium response, thereby exacerbating calcium overload in the cells. Calcium levels homeostasis maintained by a variety of calcium pumps and antiporters in the plasma membrane, endoplasmic reticulum and mitochondria. Ca2+-ATPases use energy inherent in ATP hydrolysis to pump calcium ions across the plasma membrane by active transport. These pumps have high affinity but low capacity, pumping out one Ca2+ ion for each molecule of ATP hydrolyzed. Sodium calcium exchangers act as antiporters use the sodium gradient across the plasma membrane to exchange calcium ions for sodium ions. However under conditions of ischemia, due to poor energy (ATP) production, the sodium gradients across cell membranes are decreased thereby affect the ability antiporters to extrude Ca2+ ions (Figure 11). All these factors contribute to elevation of cytosolic calcium. Increase in cytosolic calcium activates a variety of signaling molecules that influence the fate of cell survival. For example calcium binds to calmodulin and activate CaM kinase II which phosphorylates a variety of substrates, various enzymes and transcription factors. Calcium activates calpains which degrades essential cellular proteins. Calcium also activates endonucleases and promotes cleavage of genomic DNA.

One of the key targets of elevated intracellular calcium is the mitochondria, which undergoes changes that could lead to opening of the permeability transition pore (Nickells, 2004). The mitochondrial calcium antiporter is a low affinity high capacity calcium transporter that pumps calcium ions into the mitochondria upon elevation of cytoplasmic calcium. Ca2+ build up in the mitochondria produces mitochondrial swelling by dissipating the voltage gradient between the outer and inner mitochondrial membrane. The inner mitochondrial membrane is flexible and thrown into multiple folds called cristae, and is therefore able to withstand the increase in volume. However the outer mitochondria membrane is unable to accommodate the increase in volume and ruptures, leading to release of cytochrome c from the mitochondria. The released cytochrome c forms a complex with apoptotic protein activating factor-1 (APAF-1) and caspase 9 to form the apoptosome which in turns activates the caspases which cleave a variety of structural and regulatory protein thereby leading to apoptotic death of cells.

Excitatory amino acid transporters (EAATs): After glutamate is released into the synaptic cleft, it is not degraded since there are no extracellular enzymes for its degradation. Glutamatergic transmission is terminated by rapid uptake of glutamate by a variety of specific glutamate transporters which are called excitatory amino acid transporters (EAATs) (Beretta et al., 2003). There are several classes of EAATs including EAAT1 (GLAST), EAAT2 (GLT), EAAT3 (EAAC), EAAT4 and EAAT5 (expressed mainly in the retina) each of which is encoded by distinct genes (Beretta et al., 2003). EAAT1 expression has been observed mainly in astrocytes throughout the CNS. EAAT1 is a plasma membrane bound protein and rarely detected in the cytoplasm. EAAT2 is also a plasma membrane protein expressed in astrocytes in various cerebral areas. EAAT3 is a major excitatory amino acid transporter in the neurons and highly expressed in hippocampus, cerebellum, and basal ganglia. EAAT4 expressed has been observed both in the cytoplasm and plasma membrane. EAAT4 is

Neuroprotection in Glaucoma 163

Fig. 12. Ca2+ and Mitochondrial Permeability Transition Pore. One of the consequences of elevation of intracellular calcium is the opening of permeability transition pore, which is a conductance pore comprising of a complex of adenine nucleotide translocator (ANT) (in the inner mitochondrial membrane) and voltage-dependent anion channel (in the outer membrane). Under conditions of cellular stress, the complex forms an open pore at the junction of the outer and inner mitochondrial membrane. Opening of the opens dissipates the ionic gradient across the mitochondrial membrane, produces mitochondrial swelling and release of Ca2+ from the mitochondria. Cytochrome c (Cyt c) is another factor that is released from the mitochondria due to opening of the PTP and rupture of the outer mitochondrial membrane. The released cytochrome c forms a complex with procaspase 9 and apoptotic protein activating factor-1 (APAF-1) to activate the caspase cascade and

Excitotoxicity due to elevation of glutamate concentrations is an attractive hypothesis to account for retinal ganglion cell death in glaucoma. However, there is no consistent evidence for increased glutamate in animal models of glaucoma. Dreyer et al (1996) found a 2-fold increase in glutamate levels in human glaucoma patients compared to control subjects. The study also found 6-8 fold higher levels of vitreal glutamate in monkeys with experimentally-induced ocular hypertension. Another study found 5-fold higher levels of glutamate in dogs with primary glaucoma, compared with normal dogs. However two subsequent studies carried out in primates found no significant increase in vitreal glutamate in IOP elevated monkey eyes, compared to those in control eyes (Carter-Dawson et al., 2002; Wamsley et al., 2005). It is possible that the confounding factors such as increased activity of EAATs in glial cells that could be masking the increased glutamate concentrations that may occur in a narrow time window following ocular hypertension. Another significant omission in many of these studies is assessment of glutamate levels in the retina, since glial cells in the retina including Muller cells and astrocytes could be

promote apoptosis

**4.1 Glutamate elevation in glaucoma**

Fig. 11. Calcium homeostasis in cells. Intracellular calcium is elevated mainly by ionotropic receptors (for example, glutamate receptors), which in turn could activate voltage-sensitive calcium channels and store-operated channels. Elevated intracellular Ca2+ can produce a variety of cellular changes by binding to calmodulin and activating various signaling pathways or can be sequestered into the endoplasmic reticulum or mitochondria. Sarcoplasmic reticulum Ca2+-ATPase (SERCA) pumps promote uptake of Ca2+ into the endoplasmic reticulum. On the other hand, activation of inositol-1,4,5-trisphosphate (IP3) receptors in the endoplasmic reticulum or sarcoplasmic reticulum promote release of Ca2+ from these intracellular stores . The resting calcium is maintained at 100 nM by both uptake into the ER and Ca2+ release from cells by the action of plasma-membrane Ca2+-ATPase (PMCA). The mitochondria has a uniporter that takes up Ca2+ from the cytosol, however it can release it by reversal of the uniporter. Other mechanisms contributing to release of Ca2+ from the mitochondria include Na+/H+-dependent Ca2+ exchange, or opening of the permeability transition pore (PTP). Ca2+ efflux from cells occurs mainly by the PMCA, which binds calmodulin and has a high affinity for Ca2+

localized in the plasma membrane mainly in Purkinje cells. Expression of EAATs is decreased by conditions of transient global ischemia. Treatment with different cytokines including tumor necrosis factor-α (TNF-α), interferon-γ and interleukin-1β have been shown to inhibit glutamate uptake. TNF-α appears mediate this effect by decreasing GLAST and GLT expression in astrocytes. TNF-α levels have been shown to be elevated in glaucoma primarily in glial cells (Nakagawa et al., 2006; Tezel, 2008) and this could be one factor that contributing to glutamate elevation during glaucomatous insults. These observations are significant in the light of recent studies which suggest that glial activation is an early and key event in glaucoma disease progression (Nickells, 2007).

Fig. 11. Calcium homeostasis in cells. Intracellular calcium is elevated mainly by ionotropic receptors (for example, glutamate receptors), which in turn could activate voltage-sensitive calcium channels and store-operated channels. Elevated intracellular Ca2+ can produce a variety of cellular changes by binding to calmodulin and activating various signaling pathways or can be sequestered into the endoplasmic reticulum or mitochondria. Sarcoplasmic reticulum Ca2+-ATPase (SERCA) pumps promote uptake of Ca2+ into the endoplasmic reticulum. On the other hand, activation of inositol-1,4,5-trisphosphate (IP3) receptors in the endoplasmic reticulum or sarcoplasmic reticulum promote release of Ca2+ from these intracellular stores . The resting calcium is maintained at 100 nM by both uptake into the ER and Ca2+ release from cells by the action of plasma-membrane Ca2+-ATPase (PMCA). The mitochondria has a uniporter that takes up Ca2+ from the cytosol, however it can release it by reversal of the uniporter. Other mechanisms contributing to release of Ca2+ from the mitochondria include Na+/H+-dependent Ca2+ exchange, or opening of the permeability transition pore (PTP). Ca2+ efflux from cells occurs mainly by the PMCA,

localized in the plasma membrane mainly in Purkinje cells. Expression of EAATs is decreased by conditions of transient global ischemia. Treatment with different cytokines including tumor necrosis factor-α (TNF-α), interferon-γ and interleukin-1β have been shown to inhibit glutamate uptake. TNF-α appears mediate this effect by decreasing GLAST and GLT expression in astrocytes. TNF-α levels have been shown to be elevated in glaucoma primarily in glial cells (Nakagawa et al., 2006; Tezel, 2008) and this could be one factor that contributing to glutamate elevation during glaucomatous insults. These observations are significant in the light of recent studies which suggest that glial activation is an early and

which binds calmodulin and has a high affinity for Ca2+

key event in glaucoma disease progression (Nickells, 2007).

Fig. 12. Ca2+ and Mitochondrial Permeability Transition Pore. One of the consequences of elevation of intracellular calcium is the opening of permeability transition pore, which is a conductance pore comprising of a complex of adenine nucleotide translocator (ANT) (in the inner mitochondrial membrane) and voltage-dependent anion channel (in the outer membrane). Under conditions of cellular stress, the complex forms an open pore at the junction of the outer and inner mitochondrial membrane. Opening of the opens dissipates the ionic gradient across the mitochondrial membrane, produces mitochondrial swelling and release of Ca2+ from the mitochondria. Cytochrome c (Cyt c) is another factor that is released from the mitochondria due to opening of the PTP and rupture of the outer mitochondrial membrane. The released cytochrome c forms a complex with procaspase 9 and apoptotic protein activating factor-1 (APAF-1) to activate the caspase cascade and promote apoptosis

#### **4.1 Glutamate elevation in glaucoma**

Excitotoxicity due to elevation of glutamate concentrations is an attractive hypothesis to account for retinal ganglion cell death in glaucoma. However, there is no consistent evidence for increased glutamate in animal models of glaucoma. Dreyer et al (1996) found a 2-fold increase in glutamate levels in human glaucoma patients compared to control subjects. The study also found 6-8 fold higher levels of vitreal glutamate in monkeys with experimentally-induced ocular hypertension. Another study found 5-fold higher levels of glutamate in dogs with primary glaucoma, compared with normal dogs. However two subsequent studies carried out in primates found no significant increase in vitreal glutamate in IOP elevated monkey eyes, compared to those in control eyes (Carter-Dawson et al., 2002; Wamsley et al., 2005). It is possible that the confounding factors such as increased activity of EAATs in glial cells that could be masking the increased glutamate concentrations that may occur in a narrow time window following ocular hypertension. Another significant omission in many of these studies is assessment of glutamate levels in the retina, since glial cells in the retina including Muller cells and astrocytes could be

Neuroprotection in Glaucoma 165

to analyze the significance of changes in metabotropic glutamate receptors in glaucoma and

Despite numerous observations about excitotoxic cell death of retinal ganglion cells and loss of inner plexiform layer, one study reported no effect of NMDA on retinal ganglion cells (Ullian et al., 2004). The study found that NMDA treatment killed mainly the amacrine cells, while retinal ganglion cells were unaffected. This study was unable to reproduce the NMDA-mediated cell death of cultured primary retinal ganglion cells that was observed in many of the previous studies. There are many possibilities for this apparent discrepancy between various research findings about excitotoxicity in retinal ganglion cells. RGCs are highly dependent on trophic factor-mediated signaling for their cell survival. Many of the earlier studies employed NMDA treatment in cell culture conditions that did not have the optimum levels of neurotrophins and trophic factors which could account for differences in the findings. Depending upon the concentration of neurotrophins in the culture medium of retinal ganglion cells, there could be variation in viability of the cells, which could account for variations in the data for excitotoxicity. For instance BDNF has been shown to inhibit the activation of Bim, a pro-apoptotic factor that is important for promoting apoptosis of trophic-factor deprived RGCs. Thus the experimental conditions of primary culture could greatly influence the outcome of experiments when excitotoxicity of NMDA is assessed in primary cultures of retinal ganglion cells. The localization of NMDA receptors is another factor contributing to susceptibility to excitotoxicity. Chen and Diamond (2002) report that NMDA receptors are localized predominantly in the extrasynaptic region suggesting that NMDA receptors are less likely to be overactivated by synaptic events. It is unclear how this distribution of

receptors would contribute to excitotoxicity of retinal ganglion cells.

neuroprotective agents in these experimental models of glaucoma.

relevance to neurodegeneration in glaucoma.

Cell culture experiments with glutamate are often problematic due to poor solubility of L-glutamic acid and high concentrations of glutamate tend to generate artifacts due to acidification of the cell culture medium. Some investigators use monosodium glutamate to circumvent this problem, but it is unclear if this has different binding properties to glutamate receptors. It would be interesting to analyze glutamate levels in a chronic animal model of ocular hypertension and determine if NMDA antagonist would be effective as

Since NMDA receptor activity, is important for synaptic plasticity and normal neuron physiology, many NMDA antagonist that block all NMDA activity have undesirable side effects. In contrast, studies by Stuart Lipton's group demonstrated that memantine, an adamantane derivative, preferentially blocks excessive NMDA receptor activity without disrupting normal activity (Lipton, 2004). Memantine acts as an open-channel blocker by preferential binding when there is overstimulation of the receptor and does not appreciably bind to the receptor channel and interfere with normal channel activity and neurotransmission. Memantine was found to be well tolerated in patients and has been approved by FDA for treatment of dementia in Alzheimer's disease patients. Studies with the uncompetitive NMDA antagonist, memantine, met with a degree of success in ocular hypertensive rats. However phase III clinical trials with memantine were largely unsuccessful and patients showed no improvement in visual field. This study raises several issues about the contribution of NMDA receptor activation in neurodegeneration in glaucoma patients. The involvement of glutamate excitotoxicity in retinal ganglion cell death needs further investigation and further studies are necessary to understand its

their role in neurodegeneration.

paracrine sources of glutamate that contribute to excitotoxiciy. A more detailed analysis of various retinal sources of glutamate is necessary for a comprehensive assessment of glutamate elevation in glaucoma.

#### **4.2 Excitotoxic cell death of retinal ganglion cells**

Excitotoxicity is a recurring theme in the pathogenesis of retinal ganglion cell death, however the detailed cellular and biochemical mechanisms have eluded understanding for the past five decades. There are several unanswered questions about the relevance of excitotoxicity in glaucoma. The basic premise of elevation of glutamate needs further evaluation in both animal models of ocular hypertension and in human patients. If an increase in glutamate concentrations does occur in glaucoma, it is unclear if it is secondary to ischemia/hypoxia at the optic nerve head. Treatment with MK801 an NMDA glutamate receptor antagonist prevented apoptotic cell death of RGCs in ischemic rat retina after 12 h after insult (Ju et al., 2008). If an increase in glutamate occurs independent of ischemia, the underlying mechanisms for glutamate efflux from glial cells are not yet clear. The major line of evidence for excitotoxic cell death of retinal ganglion cells was from animal studies in which injection of nanomolar amounts of NMDA produce a loss of inner retinal neurons, particularly the retinal ganglion cells and inner plexiform layers. For instance, studies (Silliprandi et al., 1992) have shown that a single intravitreal injection of 20 nmole of NMDA resulted in 70% loss of cells with a soma diameter of greater than 8 microns in the ganglion cell layer, which were presumed to be retinal ganglion cells. Similar observations were made by Manabe and Lipton (2002) who demonstrated 80% retinal ganglion cell death after intravitreal injection of 20 nmole of NMDA in rats. Treatment with MK801, an uncompetitive NMDA antagonist was shown to block NMDA-mediated loss of retinal ganglion cells. A more detailed analysis of retinal ganglion cell death by excitotoxicity emerged from in vitro studies using primary cultures of retinal ganglion cells. Using chick retinal cells, Ferreira et al. demonstrated that under sodium-free conditions (to block activation of VGCC), calcium entry through NMDA receptors was sufficient to produce cell death. Hahn et al. (1988) showed that the extracellular Ca2+ concentration, plays a key role in glutamate-induced cell death in retinal ganglion cells. Under these conditions, both Mg2+ and the amino acid antagonist MK-801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo-(alpha,gamma)-cyclohepten-5, 10-imine maleate], blockers of N-methyl-D-aspartate receptor-coupled ion channels, completely blocked cell death induced by glutamate. The study suggests that Ca2+ entry through N-methyl-D-aspartate-activated channels is responsible for retinal ganglion cell death. Another NMDA antagonist, eliprodil (1 µM) was also found be very effective in protecting cultured retinal ganglion cells from NMDA-mediated cell death (Pang et al., 1999). Activation of p38 MAP kinase appears to mediate some of the neurotoxic effects of NMDA since treatment with SB203580 (a specific inhibitor of p38 MAP kinase) is effective in protecting against NMDA-mediated cell death (Manabe and Lipton, 2003). Most of the studies that demonstrate an acute effect of NMDA in producing neurodegeneration in the inner retina, may have limited relevance to primary open angle glaucoma which is a chronic neurodegenerative disease, in which clinical manifestation occurs over a period of several years. Perhaps, it would be worthwhile to study the involvement of metabotropic glutamate receptors in neurodegeneration in glaucoma. One study reported changes in several metabotropic glutamate receptors, particularly mGluR2 which was increased nearly 10-fold after ocular hypertension in DBA/2J mice (Dyka et al., 2004). Additional studies are needed

paracrine sources of glutamate that contribute to excitotoxiciy. A more detailed analysis of various retinal sources of glutamate is necessary for a comprehensive assessment of

Excitotoxicity is a recurring theme in the pathogenesis of retinal ganglion cell death, however the detailed cellular and biochemical mechanisms have eluded understanding for the past five decades. There are several unanswered questions about the relevance of excitotoxicity in glaucoma. The basic premise of elevation of glutamate needs further evaluation in both animal models of ocular hypertension and in human patients. If an increase in glutamate concentrations does occur in glaucoma, it is unclear if it is secondary to ischemia/hypoxia at the optic nerve head. Treatment with MK801 an NMDA glutamate receptor antagonist prevented apoptotic cell death of RGCs in ischemic rat retina after 12 h after insult (Ju et al., 2008). If an increase in glutamate occurs independent of ischemia, the underlying mechanisms for glutamate efflux from glial cells are not yet clear. The major line of evidence for excitotoxic cell death of retinal ganglion cells was from animal studies in which injection of nanomolar amounts of NMDA produce a loss of inner retinal neurons, particularly the retinal ganglion cells and inner plexiform layers. For instance, studies (Silliprandi et al., 1992) have shown that a single intravitreal injection of 20 nmole of NMDA resulted in 70% loss of cells with a soma diameter of greater than 8 microns in the ganglion cell layer, which were presumed to be retinal ganglion cells. Similar observations were made by Manabe and Lipton (2002) who demonstrated 80% retinal ganglion cell death after intravitreal injection of 20 nmole of NMDA in rats. Treatment with MK801, an uncompetitive NMDA antagonist was shown to block NMDA-mediated loss of retinal ganglion cells. A more detailed analysis of retinal ganglion cell death by excitotoxicity emerged from in vitro studies using primary cultures of retinal ganglion cells. Using chick retinal cells, Ferreira et al. demonstrated that under sodium-free conditions (to block activation of VGCC), calcium entry through NMDA receptors was sufficient to produce cell death. Hahn et al. (1988) showed that the extracellular Ca2+ concentration, plays a key role in glutamate-induced cell death in retinal ganglion cells. Under these conditions, both Mg2+ and the amino acid antagonist MK-801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo-(alpha,gamma)-cyclohepten-5, 10-imine maleate], blockers of N-methyl-D-aspartate receptor-coupled ion channels, completely blocked cell death induced by glutamate. The study suggests that Ca2+ entry through N-methyl-D-aspartate-activated channels is responsible for retinal ganglion cell death. Another NMDA antagonist, eliprodil (1 µM) was also found be very effective in protecting cultured retinal ganglion cells from NMDA-mediated cell death (Pang et al., 1999). Activation of p38 MAP kinase appears to mediate some of the neurotoxic effects of NMDA since treatment with SB203580 (a specific inhibitor of p38 MAP kinase) is effective in protecting against NMDA-mediated cell death (Manabe and Lipton, 2003). Most of the studies that demonstrate an acute effect of NMDA in producing neurodegeneration in the inner retina, may have limited relevance to primary open angle glaucoma which is a chronic neurodegenerative disease, in which clinical manifestation occurs over a period of several years. Perhaps, it would be worthwhile to study the involvement of metabotropic glutamate receptors in neurodegeneration in glaucoma. One study reported changes in several metabotropic glutamate receptors, particularly mGluR2 which was increased nearly 10-fold after ocular hypertension in DBA/2J mice (Dyka et al., 2004). Additional studies are needed

glutamate elevation in glaucoma.

**4.2 Excitotoxic cell death of retinal ganglion cells**

to analyze the significance of changes in metabotropic glutamate receptors in glaucoma and their role in neurodegeneration.

Despite numerous observations about excitotoxic cell death of retinal ganglion cells and loss of inner plexiform layer, one study reported no effect of NMDA on retinal ganglion cells (Ullian et al., 2004). The study found that NMDA treatment killed mainly the amacrine cells, while retinal ganglion cells were unaffected. This study was unable to reproduce the NMDA-mediated cell death of cultured primary retinal ganglion cells that was observed in many of the previous studies. There are many possibilities for this apparent discrepancy between various research findings about excitotoxicity in retinal ganglion cells. RGCs are highly dependent on trophic factor-mediated signaling for their cell survival. Many of the earlier studies employed NMDA treatment in cell culture conditions that did not have the optimum levels of neurotrophins and trophic factors which could account for differences in the findings. Depending upon the concentration of neurotrophins in the culture medium of retinal ganglion cells, there could be variation in viability of the cells, which could account for variations in the data for excitotoxicity. For instance BDNF has been shown to inhibit the activation of Bim, a pro-apoptotic factor that is important for promoting apoptosis of trophic-factor deprived RGCs. Thus the experimental conditions of primary culture could greatly influence the outcome of experiments when excitotoxicity of NMDA is assessed in primary cultures of retinal ganglion cells. The localization of NMDA receptors is another factor contributing to susceptibility to excitotoxicity. Chen and Diamond (2002) report that NMDA receptors are localized predominantly in the extrasynaptic region suggesting that NMDA receptors are less likely to be overactivated by synaptic events. It is unclear how this distribution of receptors would contribute to excitotoxicity of retinal ganglion cells.

Cell culture experiments with glutamate are often problematic due to poor solubility of L-glutamic acid and high concentrations of glutamate tend to generate artifacts due to acidification of the cell culture medium. Some investigators use monosodium glutamate to circumvent this problem, but it is unclear if this has different binding properties to glutamate receptors. It would be interesting to analyze glutamate levels in a chronic animal model of ocular hypertension and determine if NMDA antagonist would be effective as neuroprotective agents in these experimental models of glaucoma.

Since NMDA receptor activity, is important for synaptic plasticity and normal neuron physiology, many NMDA antagonist that block all NMDA activity have undesirable side effects. In contrast, studies by Stuart Lipton's group demonstrated that memantine, an adamantane derivative, preferentially blocks excessive NMDA receptor activity without disrupting normal activity (Lipton, 2004). Memantine acts as an open-channel blocker by preferential binding when there is overstimulation of the receptor and does not appreciably bind to the receptor channel and interfere with normal channel activity and neurotransmission. Memantine was found to be well tolerated in patients and has been approved by FDA for treatment of dementia in Alzheimer's disease patients. Studies with the uncompetitive NMDA antagonist, memantine, met with a degree of success in ocular hypertensive rats. However phase III clinical trials with memantine were largely unsuccessful and patients showed no improvement in visual field. This study raises several issues about the contribution of NMDA receptor activation in neurodegeneration in glaucoma patients. The involvement of glutamate excitotoxicity in retinal ganglion cell death needs further investigation and further studies are necessary to understand its relevance to neurodegeneration in glaucoma.

Neuroprotection in Glaucoma 167

human glaucomatous optic nerves as compared with age-matched controls Rogers et al. (1997) demonstrated an increase in ETB expression in glial cells in the optic nerve, after optic nerve transection. ET-1 acts through its receptors to promote proliferation and activation of optic nerve head astrocytes, which are key steps in the progression of glaucoma (Prasanna et al., 2002). Yang et al. (2007) showed that ETB mRNA expression in the retina increased in a rodent elevated IOP model of glaucoma, from as early as 1 day and persisted up to 8 weeks of IOP elevation. It therefore appears that endothelin receptor activation could be an early event in the etiology of glaucoma. Krishnamoorthy et al. (2008) showed that ETB receptor expression is increased in RGCs after intravitreal injection of ET-1 and this was accompanied by apoptosis of RGCs. ET-1 mediated apoptosis was attenuated in ETB receptor-deficient rats (Krishnamoorthy et al., 2008). Recent studies from Simon John's lab showed that blocking endothelin receptors using bosentan (antagonist for both ETA and ETB receptors) is neuroprotective in a mouse ocular hypertension model of glaucoma (Howell et al., 2011). It is becoming increasingly evident from several corroborative observations that the endothelin system may play a pivotal role in neurodegeneration in glaucoma. Together these studies suggest the possibility of using endothelin antagonists as

Sigma-1 receptors have emerged as a promising new neuroprotective candidate to protect RGCs from many of the noxious factors that are associated with the disease process of glaucoma (Dun et al., 2007). Sigma-1 receptors are a 26 kD transmembrane protein found on the endoplasmic reticulum (ER) that translocate from the ER to interact with ionotropic channels located on the plasma membrane (Hayahsi and Su 2007). This molecular signaling pathway enables the ubiquitously expressed sigma-1 receptor to associate and regulate many ligand gated ion channels that are found on the plasma membrane of many different cell types throughout the body (Hayashi and Su 2007; Zhang and Cuevas 2002). Sigma-1 receptors have been shown to be expressed in the retina, with the predominating level of expression in the retinal ganglion cell layer (Liu et al., 2010). There are several factors that contribute to neuroprotective ability of sigma receptors. Sigma-1 receptor's ability to bind and associate with L-type voltage gated calcium channels, regulate neuronal intracellular calcium concentrations when exposed to ischemic conditions, prevent glutamate excitotoxicity of RGCs when exposed to sigma-1 agonist (+)-pentazocine are some of the key mechanisms underlying sigma-1's neuroprotective effects (Tchedre et al., 2008; Katnik at al., 2006; Dun et al., 2007). Other pathways affected by sigma-1 receptor include attenuation of intrinsic death signal of glutamate-exposed retinal cell lines, which is a likely candidate to maintain the viability, and homeostatic intracellular calcium regulation of RGCs when they are exposed to a number of noxious stimuli that cause RGC apoptosis (Tchedre and Yorio 2008). Lastly, sigma-1 receptor stimulation has also demonstrated *in vivo* protection against retinal degeneration in a diabetic retinopathy animal model (Smith et al., 2008). More pre-clinical research needs to be preformed to demonstrate the neuroprotective efficacy of sigma

Another molecule that has emerged as a key contributor to glaucoma progression is the cytokine, tumor necrosis factor-α (TNF-α) (Tezel, 2008). In the anterior chamber of the eye,

potential neuroprotective agents for glaucoma treatment.

receptors in glaucomatous animal models.

**6.3 Tumor necrosis factor-**α

**6.2 Sigma-1 receptor**

#### **5. Alpha-2-adrenergic agonists**

Alpha-2 adrenergic agonists including clonidine and brimonidine have been known to reduce intraocular pressure, however clonidine produces a number of undesirable cardiovascular side effects. Brimonidine has a structure similar to clonidine, and is effective loweing IOP both in normotensive and ocular hypertensive primates (Burke and Potter, 1986). The mechanism underlying its ocular hypotensive effects are possibly related to reducing aqueous humor formation, since alpha-2-adrenergic receptors have been shown to be expressed in the iris and ciliary body. In recent years, studies have shown that in addition to lowering IOP, brimonidine has neuroprotective effects in animal models of glaucoma (Wheeler et al., 2003; Ahmed et al., 2001). For instance, in a rat model of elevated IOP, brimonidine administration initiated 10 days after IOP elevation prevented any further loss of ganglion cells. In vehicle- or timolol-treated rats, ganglion cell loss continued to occur (Woldmussie et al., 2001). In another glaucoma model, seven days after inducing transient ischaemia, there was loss of approximately half of the RGC population. Topical pretreatment with 0.1% or 0.5% brimonidine attenuated ischaemia-induced RGC death. Brimonidine appers to preserve RGC survival and protect against a variety of glaucomatous insults. For instance, Lee et al. (2010) showed that brimonidine increased survival of rat RGCs in the presence of glutamate neurotoxicity, oxidative stress, and hypoxia.

#### **6. Other emerging targets for neuroprotection**

#### **6.1 Endothelins**

Endothelin-1 (ET-1) is a potent vasoactive peptide (Yanagisawa et al., 1988), has gained attention for its neurodegenerative role in glaucoma (Yorio et al., 2002). However the precise mechanisms underlying ET-1 mediated neurodegeneration are not completely understood. ET-1 levels are elevated in the aqueous humor of primary open angle glaucoma patients (Noske et al., 1997; Tezel et al., 1997) and in animal models of glaucoma (Kallberg et al., 2002; Thanos and Naskar 2004; and Prasanna et al., 2005). The clinical relevance of these findings is not completely clear but it appears plausible that ET-1 in aqueous humor could be secreted in response to an increase in IOP. There is considerable evidence to suggest that ET-1 could produce optic nerve damage similar to that seen in glaucoma. For instance, continuous peribulbar administration of ET-1 in primates produces optic nerve damage, similar to that seen in glaucoma (Orgul et al., 1996; Cioffi and Sullivan, 1999). Lau et al. (2005) have shown that a single ET-1 injection into rat eyes promoted loss of retinal ganglion cells, accompanied by increased GFAP labeling in the Muller cells end feet and astrocytic cell layer in retina and optic nerve. Chauhan et al. (2004) demonstrated that chronic administration of low doses ET-1 that do not appreciably alter blood flow in the retrobulbar region of the optic nerve, also results in a progressive loss of retinal ganglion cells and their axons without changes in optic disc morphology.

Since all known actions of ET-1 occur through binding to its receptors, it is important to understand which receptors may be mediating its damaging effects in glaucomatous optic neuropathy. Endothelin-1 acts mainly through two classes of receptors, the ETA and ETB receptors (Rubanyi and Polokoff, 1994). Both ETA and ETB belong to the rhodopsin superfamily of G-protein coupled receptors. Recently studies suggest that the endothelin B (ETB) receptor may be involved in mediating ET-1's neurodegenerative effects. For instance, Wang et al. (2006) showed increased immunohistochemical staining for ETB receptors in

Alpha-2 adrenergic agonists including clonidine and brimonidine have been known to reduce intraocular pressure, however clonidine produces a number of undesirable cardiovascular side effects. Brimonidine has a structure similar to clonidine, and is effective loweing IOP both in normotensive and ocular hypertensive primates (Burke and Potter, 1986). The mechanism underlying its ocular hypotensive effects are possibly related to reducing aqueous humor formation, since alpha-2-adrenergic receptors have been shown to be expressed in the iris and ciliary body. In recent years, studies have shown that in addition to lowering IOP, brimonidine has neuroprotective effects in animal models of glaucoma (Wheeler et al., 2003; Ahmed et al., 2001). For instance, in a rat model of elevated IOP, brimonidine administration initiated 10 days after IOP elevation prevented any further loss of ganglion cells. In vehicle- or timolol-treated rats, ganglion cell loss continued to occur (Woldmussie et al., 2001). In another glaucoma model, seven days after inducing transient ischaemia, there was loss of approximately half of the RGC population. Topical pretreatment with 0.1% or 0.5% brimonidine attenuated ischaemia-induced RGC death. Brimonidine appers to preserve RGC survival and protect against a variety of glaucomatous insults. For instance, Lee et al. (2010) showed that brimonidine increased survival of rat

RGCs in the presence of glutamate neurotoxicity, oxidative stress, and hypoxia.

Endothelin-1 (ET-1) is a potent vasoactive peptide (Yanagisawa et al., 1988), has gained attention for its neurodegenerative role in glaucoma (Yorio et al., 2002). However the precise mechanisms underlying ET-1 mediated neurodegeneration are not completely understood. ET-1 levels are elevated in the aqueous humor of primary open angle glaucoma patients (Noske et al., 1997; Tezel et al., 1997) and in animal models of glaucoma (Kallberg et al., 2002; Thanos and Naskar 2004; and Prasanna et al., 2005). The clinical relevance of these findings is not completely clear but it appears plausible that ET-1 in aqueous humor could be secreted in response to an increase in IOP. There is considerable evidence to suggest that ET-1 could produce optic nerve damage similar to that seen in glaucoma. For instance, continuous peribulbar administration of ET-1 in primates produces optic nerve damage, similar to that seen in glaucoma (Orgul et al., 1996; Cioffi and Sullivan, 1999). Lau et al. (2005) have shown that a single ET-1 injection into rat eyes promoted loss of retinal ganglion cells, accompanied by increased GFAP labeling in the Muller cells end feet and astrocytic cell layer in retina and optic nerve. Chauhan et al. (2004) demonstrated that chronic administration of low doses ET-1 that do not appreciably alter blood flow in the retrobulbar region of the optic nerve, also results in a progressive loss of retinal ganglion cells and their

Since all known actions of ET-1 occur through binding to its receptors, it is important to understand which receptors may be mediating its damaging effects in glaucomatous optic neuropathy. Endothelin-1 acts mainly through two classes of receptors, the ETA and ETB receptors (Rubanyi and Polokoff, 1994). Both ETA and ETB belong to the rhodopsin superfamily of G-protein coupled receptors. Recently studies suggest that the endothelin B (ETB) receptor may be involved in mediating ET-1's neurodegenerative effects. For instance, Wang et al. (2006) showed increased immunohistochemical staining for ETB receptors in

**6. Other emerging targets for neuroprotection**

axons without changes in optic disc morphology.

**6.1 Endothelins**

**5. Alpha-2-adrenergic agonists**

human glaucomatous optic nerves as compared with age-matched controls Rogers et al. (1997) demonstrated an increase in ETB expression in glial cells in the optic nerve, after optic nerve transection. ET-1 acts through its receptors to promote proliferation and activation of optic nerve head astrocytes, which are key steps in the progression of glaucoma (Prasanna et al., 2002). Yang et al. (2007) showed that ETB mRNA expression in the retina increased in a rodent elevated IOP model of glaucoma, from as early as 1 day and persisted up to 8 weeks of IOP elevation. It therefore appears that endothelin receptor activation could be an early event in the etiology of glaucoma. Krishnamoorthy et al. (2008) showed that ETB receptor expression is increased in RGCs after intravitreal injection of ET-1 and this was accompanied by apoptosis of RGCs. ET-1 mediated apoptosis was attenuated in ETB receptor-deficient rats (Krishnamoorthy et al., 2008). Recent studies from Simon John's lab showed that blocking endothelin receptors using bosentan (antagonist for both ETA and ETB receptors) is neuroprotective in a mouse ocular hypertension model of glaucoma (Howell et al., 2011). It is becoming increasingly evident from several corroborative observations that the endothelin system may play a pivotal role in neurodegeneration in glaucoma. Together these studies suggest the possibility of using endothelin antagonists as potential neuroprotective agents for glaucoma treatment.

#### **6.2 Sigma-1 receptor**

Sigma-1 receptors have emerged as a promising new neuroprotective candidate to protect RGCs from many of the noxious factors that are associated with the disease process of glaucoma (Dun et al., 2007). Sigma-1 receptors are a 26 kD transmembrane protein found on the endoplasmic reticulum (ER) that translocate from the ER to interact with ionotropic channels located on the plasma membrane (Hayahsi and Su 2007). This molecular signaling pathway enables the ubiquitously expressed sigma-1 receptor to associate and regulate many ligand gated ion channels that are found on the plasma membrane of many different cell types throughout the body (Hayashi and Su 2007; Zhang and Cuevas 2002). Sigma-1 receptors have been shown to be expressed in the retina, with the predominating level of expression in the retinal ganglion cell layer (Liu et al., 2010). There are several factors that contribute to neuroprotective ability of sigma receptors. Sigma-1 receptor's ability to bind and associate with L-type voltage gated calcium channels, regulate neuronal intracellular calcium concentrations when exposed to ischemic conditions, prevent glutamate excitotoxicity of RGCs when exposed to sigma-1 agonist (+)-pentazocine are some of the key mechanisms underlying sigma-1's neuroprotective effects (Tchedre et al., 2008; Katnik at al., 2006; Dun et al., 2007). Other pathways affected by sigma-1 receptor include attenuation of intrinsic death signal of glutamate-exposed retinal cell lines, which is a likely candidate to maintain the viability, and homeostatic intracellular calcium regulation of RGCs when they are exposed to a number of noxious stimuli that cause RGC apoptosis (Tchedre and Yorio 2008). Lastly, sigma-1 receptor stimulation has also demonstrated *in vivo* protection against retinal degeneration in a diabetic retinopathy animal model (Smith et al., 2008). More pre-clinical research needs to be preformed to demonstrate the neuroprotective efficacy of sigma receptors in glaucomatous animal models.

#### **6.3 Tumor necrosis factor-**α

Another molecule that has emerged as a key contributor to glaucoma progression is the cytokine, tumor necrosis factor-α (TNF-α) (Tezel, 2008). In the anterior chamber of the eye,

Neuroprotection in Glaucoma 169

The authors thank Dr. Thomas Yorio for critically reading the manuscript and providing

Adachi,K.,Kashii,S.,Masai,H.,Ueda,M.,Morizane,C.,Kaneda,K.,Kume,T.,Akaike,A., Honda,Y.

Allergan Inc, Press Releases on Memantine Trials, Fourth Quarter Operating Results, Jan 30

Anderson, M.G., Smith, R.S., Hawes, N.L., Zabaleta, A., Chang, B., Wiggs, J.L. & John SW.

Araie, M., and Mayama, C. (2010) Use of calcium channel blockers for glaucoma, Progress in

Araie, M., Azuma, I., Kitazawa, Y., 2003. Influence of topical betaxolol and timolol on visual

Arévalo, J.C., Yano, H., Teng, K.K. & Chao, M.V. (2004 ). A unique pathway for sustained

Badea T.C., and Nathans J. (2004). Quantitative analysis of neuronal morphologies in the

Bähr, M. (2000). Live or let die - retinal ganglion cell death and survival during development

Bahrami H. (2006) Causal models in primary open angle glaucoma. *Ophthalmic Epidemiol*.

Bai, Y., Dergham, P., Nedev, H., Xu, J., Galan, A., Rivera, J.C., ZhiHua, S., Mehta, H.M.,

Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K.,

Banin, E., Obolensky, A., Idelson, M., Hemo, I., Reinhardtz, E., Pikarsky, E., Ben-Hur, T. &

Barbacid, M. (1995). Neurotrophic factors and their receptors. *Curr Opin Cell Biol*. 7(2):148-

Bartsch, U., Oriyakhel, W., Kenna, P.F., Linke, S., Richard, G., Petrowitz, B., Humphries, P.,

derived from human embryonic stem cells*. Stem Cells.* 24:246-57.

and in the lesioned adult CNS. *Trends Neurosci.* 23:483-90.

ischemia. *Graefes Arch. Clin. Exp. Ophthalmol*. Vol. 236, pp. 766-774.

2008 http://www.allergan.com/newsroom/index.htm

glaucoma in DBA/2J mice. *Nat Genet.* 30: 81-5.

Retinal and Eye Research, 2010, 1-18

(1998).Mechanism of the pathogenesis of glutamate neurotoxicity in retinal

(2002). Mutations in genes encoding melanosomal proteins cause pigmentary

field in Japanese open-angle glaucoma patients. Jpn. J. Ophthalmol. Vol. 47, pp.

neurotrophin signaling through an ankyrin-rich membrane-spanning protein.

mouse retina visualized by using a genetically directed reporter. J Comp Neurol

Woo, S.B., Sarunic, M.V., Neet, K.E. & Saragovi, H.U. (2010). Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. *J Biol Chem.*

Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S.S., Thrasher,A.J., Fitzke, F.W., Carter, B.J., Rubin, G.S., Moore, A.T. & Ali, R.R. (2008) Effect of gene therapy on visual function in Leber's congenital

Reubinoff, B. (2006). Retinal incorporation and differentiation of neural precursors

Farrar, G.J. & Ader, M. (2008). Retinal cells integrate into the outer nuclear layer

**8. Acknowledgements**

199-207.

*EMBO J.* 23:2358-68.

480:. 331–351

4:291-298.

55.

285:39392-39400

amaurosis. *N Engl J Med* 358:2231–2239.

**9. References**

several useful comments and suggestions.

TNF-α could have beneficial effects by promoting outflow through conventional and uveoscleral pathways (Husain et al., 2008). However, TNF-α appears to produce damaging effects in the posterior segment of the eye. Several publications point to the involvement of TNF-α in glaucomatous neurodegeneration. Yang et al. (2007) showed an increase in TNFα receptor 1A expression in an ocular hypertension model of glaucoma in rodents. Increased labeling for TNF-α and its receptor was observed in glaucomatous eyes compared to controls (Tezel et al., 2001). In the same study, double immunofluorescence suggested TNF-α labeling mainly in glial cells, while TNF-α receptors were found mainly on RGCs. In a mouse model of ocular hypertension, Nakazawa et al. (2008) found increased concentrations of TNF-α in the retina, which was followed by microglial activation and loss of RGCs. The authors found that RGC loss was greatly attenuated in TNF-receptor 2-deficient mice, suggesting that TNF-α acts through TNF receptor-2 to produce neurodegeneration in glaucoma (Nakazawa et al., 2006). TNF-α promotes ET-1 release from ciliary non-pigmented ciliary epithelial cells (Prasanna et al., 1998) as well as retinal pigmented epithelium (Narayan et al., 2003), suggesting that some of TNF-α's effects could be due to the downstream effects of endothelins. The role of TNF-α in glaucomatous degeneration is an evolving area of research with important implications for further research.

#### **6.4 CD44**

CD44 is a transmembrane glycoprotein which acts as a receptor for hyaluronic acid. Recent work by several groups suggests that soluble CD44 is significantly increased in aqueous humor of primary open angle glaucoma patients (Choi et al., 2005; Budak et al., 2009; Mokbel et al., 2010). The 32kDa ectodomain fragment of soluble CD44 was found have toxic effects both in the trabecular meshwork and ganglion cells *in vitro*. The cyotoxicity of CD44 was blocked by administration of anti-CD44 antibody in vitro (Choi et al., 2005). CD44 was also found to be increased in other models of neurodegeneration such as RDS mice which is characterized by inherited retinal degeneration (Krishnamoorthy et al., 2000). More work is needed in this developing area of research to fully understand the contribution of CD44 to glaucomatous pathophysiology.

#### **7. Concluding remarks**

While the present treatment modalities for glaucoma are effective in terms of lowering intraocular pressure and slowing down neurodegeneration, there are issues with long term application of medications particularly their side effects due to prolonged use. Besides, neurodegenerative effects continue to occur in some patients despite lowering IOP. It is clear that there are numerous targets that could be exploited for developing a neuroprotective agent to reduce axon loss and apoptosis of RGCs. However, it would be imperative to develop stringent measures to assess the efficacy and potency of various test compounds in animal models of glaucoma. After careful analysis using a battery of tests and cellular and molecular assays for neuroprotection, an efficacious candidate drug could make significant progress in clinical trials, so that there would be a good chance for success with neuroprotection in humans. This would involve a concerted effort among basic scientists, clinicians and pharmacologists and should result in the development of the first generation of neuroprotective treatments for glaucoma.

#### **8. Acknowledgements**

The authors thank Dr. Thomas Yorio for critically reading the manuscript and providing several useful comments and suggestions.

#### **9. References**

168 Glaucoma - Basic and Clinical Concepts

TNF-α could have beneficial effects by promoting outflow through conventional and uveoscleral pathways (Husain et al., 2008). However, TNF-α appears to produce damaging effects in the posterior segment of the eye. Several publications point to the involvement of TNF-α in glaucomatous neurodegeneration. Yang et al. (2007) showed an increase in TNFα receptor 1A expression in an ocular hypertension model of glaucoma in rodents. Increased labeling for TNF-α and its receptor was observed in glaucomatous eyes compared to controls (Tezel et al., 2001). In the same study, double immunofluorescence suggested TNF-α labeling mainly in glial cells, while TNF-α receptors were found mainly on RGCs. In a mouse model of ocular hypertension, Nakazawa et al. (2008) found increased concentrations of TNF-α in the retina, which was followed by microglial activation and loss of RGCs. The authors found that RGC loss was greatly attenuated in TNF-receptor 2-deficient mice, suggesting that TNF-α acts through TNF receptor-2 to produce neurodegeneration in glaucoma (Nakazawa et al., 2006). TNF-α promotes ET-1 release from ciliary non-pigmented ciliary epithelial cells (Prasanna et al., 1998) as well as retinal pigmented epithelium (Narayan et al., 2003), suggesting that some of TNF-α's effects could be due to the downstream effects of endothelins. The role of TNF-α in glaucomatous degeneration is an evolving area of research with important implications for

CD44 is a transmembrane glycoprotein which acts as a receptor for hyaluronic acid. Recent work by several groups suggests that soluble CD44 is significantly increased in aqueous humor of primary open angle glaucoma patients (Choi et al., 2005; Budak et al., 2009; Mokbel et al., 2010). The 32kDa ectodomain fragment of soluble CD44 was found have toxic effects both in the trabecular meshwork and ganglion cells *in vitro*. The cyotoxicity of CD44 was blocked by administration of anti-CD44 antibody in vitro (Choi et al., 2005). CD44 was also found to be increased in other models of neurodegeneration such as RDS mice which is characterized by inherited retinal degeneration (Krishnamoorthy et al., 2000). More work is needed in this developing area of research to fully understand the contribution of CD44 to

While the present treatment modalities for glaucoma are effective in terms of lowering intraocular pressure and slowing down neurodegeneration, there are issues with long term application of medications particularly their side effects due to prolonged use. Besides, neurodegenerative effects continue to occur in some patients despite lowering IOP. It is clear that there are numerous targets that could be exploited for developing a neuroprotective agent to reduce axon loss and apoptosis of RGCs. However, it would be imperative to develop stringent measures to assess the efficacy and potency of various test compounds in animal models of glaucoma. After careful analysis using a battery of tests and cellular and molecular assays for neuroprotection, an efficacious candidate drug could make significant progress in clinical trials, so that there would be a good chance for success with neuroprotection in humans. This would involve a concerted effort among basic scientists, clinicians and pharmacologists and should result in the development of the first generation

further research.

glaucomatous pathophysiology.

of neuroprotective treatments for glaucoma.

**7. Concluding remarks**

**6.4 CD44**

Neuroprotection in Glaucoma 171

Carter-Dawson, L., Crawford, M.L., Harwerth, R.S. & Smith, E.L. 3rd., Feldman, R., Shen,

Chao, MV. & Hempstead, BL (1995). p75 and Trk: a two-receptor system. *Trends Neurosci*.

Chao, MV. (2003). Neurotrophins and their receptors: a convergence point for many

Chauhan, B.C., LaVatte, T.L., Jollimore, C.A., Yu, P.K., Reitsamer, H.A., Kelly, M.E.M., Yu,

Chen, H. & Weber, AJ. (2004). Brain-derived neurotrophic factor reduces TrkB protein and

Chen, S. & Diamond, J.S. (2002) Synaptically released glutamate activates extrasynaptic

Chen, Y.N., Yamada, H., Mao, W., Uchida, S., Matsuyama, S., Aihara, M., and Araie,

Cheng, L., Sapieha, P., Kittlerova, P., Hauswirth, WW., Di Polo, A. (2002). TrkB gene transfer

Cheon, E.W., Kim, Y.H., Cho, Y.Y., Kim, H.J., Kang, S.S., Cho, G.J., Yoo, J.M., Song, J.K.,

Cheon, E.W., Park, C.H., Kim, Y.S., Cho, C.H., Chung, Y.C., Kwon, J.G., Yoo, J.M., Choi,

Chikar, JA., Colesa, DJ., Swiderski, DL., Di Polo, A., Raphael, Y., Pfingst, BE. (2008). Over-

Cioffi, G.A. & Sullivan, P. (1999) The effect of chronic ischemia on the primate optic nerve.

Clark, A.F. & Yorio, T. *Ophthalmic Drug Discovery. Nature Review Drug Discovery.* 2: 448-459 Clarke, PG., Posada, A., Primi, MP., Castagné, V. (1998). Neuronal death in the central nervous system during development. *Biomed Pharmacother*. 52:356-62.

effects of beta-adrenergic antagonists. Brain Res. 1148: 28-37.

ischemic injury of the retina. Exp. Eye Res. 75: 591-601.

neuronal death. Brain Res. 1069: 75-85.

vitro. Invest Ophthalmol Vis Sci. 46:214-222.

*Eur. J. Ophthalmol.* 9: S34-S36

chronic optic neuropathy in rat. *Invest. Ophthalmol. Vis. Sci.* 45: 144-152. Chen H-SV, Pellegrini JW, Aggarwal SW, Lei SZ, Warach S, Jensen FE and Lipton SA.

D-Yi., Tremblay, F. & Archibald, MA. (2004) Model of endothelin-1-induced

(1992). Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. *J*

mRNA in the normal retina and following optic nerve crush in adult rats. *Brain Res.*

NMDA receptors on cells in the ganglion cell layer of rat retina. J. Neurosci. 22:

M.(2007). Hypoxia-induced retinal ganglion cell death and the neuroprotective

protects retinal ganglion cells from axotomy-induced death in vivo*. J Neurosci*.

Choi, W.S., 2002. Betaxolol, a b1-adrenoceptor antagonist, protects a transient

W.S., Cho, G.J., 2006. Protective effects of betaxolol in eyes with kainic acid-induced